{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Task-related articles and sentences retrieval based on two-level of tf-idf with result summary for each task.\n",
    "#### Goal\n",
    "Given a large number of literature and queries of interest, retrieve the most relevant information to the queries from the literature. \n",
    "#### Approach\n",
    "Since there is no ground-truth answer to each task, we model each task as an information retrieval problem and adopt the tf-idf features to quantize the similarity between queries of each task and articles. Specifically, we implement a two-level tf-idf information retrieval system. On the first level, the most relevant articles are retrieved for each task. On the second level, the most relevant sentences are retrieved from the articles retrieved on the first level. The articles/sentences are ranked based on cosine similarity between tf-idf feature vectors of articles/sentences and the target query. The same approach is applicable to all 10 tasks in this challenge. Once all the articles are vectorized and indexed, they can be reloaded to quickly respond to different queries of different tasks without re-training.\n",
    "#### Afterwards analyses\n",
    "At the end of this notebook, we also provide a mixed short-cut for the articles and sentences we retrieved for each of the 10 tasks. This summary of results may not represent a professional or comprehensive analysis of all available COVID-19 studies so far, but may still serve as a reference that we hope may help inspire further examinations. We are submitting the same notebook to all tasks in case the reviewers of one task may also be interested to see the results for other tasks."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import os\n",
    "from os import listdir\n",
    "from os.path import isfile, join\n",
    "import collections\n",
    "import re\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "from nltk.tokenize import word_tokenize, sent_tokenize\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.stem import LancasterStemmer, PorterStemmer, SnowballStemmer, WordNetLemmatizer\n",
    "import time\n",
    "import string\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from scipy.spatial.distance import cdist\n",
    "import pickle\n",
    "import json"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# I. Metadata basic statistics\n",
    "We first examine the metadata to gain a deeper understanding of the dataset. We pay more attention to the abstracts as an abstract is usually a high-level summary of the discovery of a study, thus it is information-enriched. In addition, while less than half of the articles have a full-text available, most articles have an abstract provided."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Read-in metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of articles: 29500\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>authors</th>\n",
       "      <th>journal</th>\n",
       "      <th>Microsoft Academic Paper ID</th>\n",
       "      <th>WHO #Covidence</th>\n",
       "      <th>has_full_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>c630ebcdf30652f0422c3ec12a00b50241dc9bd9</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Angiotensin-converting enzyme 2 (ACE2) as a SA...</td>\n",
       "      <td>10.1007/s00134-020-05985-9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125455.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>2.002765e+09</td>\n",
       "      <td>#3252</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>53eccda7977a31e3d0f565c884da036b1e85438e</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Comparative genetic analysis of the novel coro...</td>\n",
       "      <td>10.1038/s41421-020-0147-1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...</td>\n",
       "      <td>Cell Discovery</td>\n",
       "      <td>3.003431e+09</td>\n",
       "      <td>#1861</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>210a892deb1c61577f6fba58505fd65356ce6636</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Incubation Period and Other Epidemiological Ch...</td>\n",
       "      <td>10.3390/jcm9020538</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The geographic spread of 2019 novel coronaviru...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...</td>\n",
       "      <td>Journal of Clinical Medicine</td>\n",
       "      <td>3.006065e+09</td>\n",
       "      <td>#1043</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>e3b40cc8e0e137c416b4a2273a4dca94ae8178cc</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Characteristics of and Public Health Responses...</td>\n",
       "      <td>10.3390/jcm9020575</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32093211.0</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>In December 2019, cases of unidentified pneumo...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Deng, Sheng-Qun; Peng, Hong-Juan</td>\n",
       "      <td>J Clin Med</td>\n",
       "      <td>1.776631e+08</td>\n",
       "      <td>#1999</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>92c2c9839304b4f2bc1276d41b1aa885d8b364fd</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Imaging changes in severe COVID-19 pneumonia</td>\n",
       "      <td>10.1007/s00134-020-05976-w</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125453.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Wei</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>3.006643e+09</td>\n",
       "      <td>#3242</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        sha source_x  \\\n",
       "0  c630ebcdf30652f0422c3ec12a00b50241dc9bd9      CZI   \n",
       "1  53eccda7977a31e3d0f565c884da036b1e85438e      CZI   \n",
       "2  210a892deb1c61577f6fba58505fd65356ce6636      CZI   \n",
       "3  e3b40cc8e0e137c416b4a2273a4dca94ae8178cc      CZI   \n",
       "4  92c2c9839304b4f2bc1276d41b1aa885d8b364fd      CZI   \n",
       "\n",
       "                                               title  \\\n",
       "0  Angiotensin-converting enzyme 2 (ACE2) as a SA...   \n",
       "1  Comparative genetic analysis of the novel coro...   \n",
       "2  Incubation Period and Other Epidemiological Ch...   \n",
       "3  Characteristics of and Public Health Responses...   \n",
       "4       Imaging changes in severe COVID-19 pneumonia   \n",
       "\n",
       "                          doi pmcid   pubmed_id   license  \\\n",
       "0  10.1007/s00134-020-05985-9   NaN  32125455.0  cc-by-nc   \n",
       "1   10.1038/s41421-020-0147-1   NaN         NaN     cc-by   \n",
       "2          10.3390/jcm9020538   NaN         NaN     cc-by   \n",
       "3          10.3390/jcm9020575   NaN  32093211.0     cc-by   \n",
       "4  10.1007/s00134-020-05976-w   NaN  32125453.0  cc-by-nc   \n",
       "\n",
       "                                            abstract publish_time  \\\n",
       "0                                                NaN         2020   \n",
       "1                                                NaN         2020   \n",
       "2  The geographic spread of 2019 novel coronaviru...         2020   \n",
       "3  In December 2019, cases of unidentified pneumo...         2020   \n",
       "4                                                NaN         2020   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...   \n",
       "1  Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...   \n",
       "2  Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...   \n",
       "3                   Deng, Sheng-Qun; Peng, Hong-Juan   \n",
       "4                                         Zhang, Wei   \n",
       "\n",
       "                        journal  Microsoft Academic Paper ID WHO #Covidence  \\\n",
       "0            Intensive Care Med                 2.002765e+09          #3252   \n",
       "1                Cell Discovery                 3.003431e+09          #1861   \n",
       "2  Journal of Clinical Medicine                 3.006065e+09          #1043   \n",
       "3                    J Clin Med                 1.776631e+08          #1999   \n",
       "4            Intensive Care Med                 3.006643e+09          #3242   \n",
       "\n",
       "  has_full_text  \n",
       "0          True  \n",
       "1          True  \n",
       "2          True  \n",
       "3          True  \n",
       "4         False  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#metaDataPath = \"/kaggle/input/CORD-19-research-challenge/2020-03-13/all_sources_metadata_2020-03-13.csv\"\n",
    "metaDataPath = \"~/Downloads/2020-03-13/all_sources_metadata_2020-03-13.csv\"\n",
    "metaData = pd.read_csv(metaDataPath, header = 0)\n",
    "print(\"The number of articles: \" + str(metaData.shape[0]))\n",
    "metaData.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Nan elements counts in all columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "sha                            12080\n",
       "source_x                           0\n",
       "title                            370\n",
       "doi                             3143\n",
       "pmcid                           2163\n",
       "pubmed_id                      12770\n",
       "license                        11808\n",
       "abstract                        2947\n",
       "publish_time                   11252\n",
       "authors                          946\n",
       "journal                        11709\n",
       "Microsoft Academic Paper ID    28366\n",
       "WHO #Covidence                 28264\n",
       "has_full_text                  12080\n",
       "dtype: int64"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metaData.isnull().sum()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Literature source distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "sourceDic = collections.defaultdict(int)\n",
    "for s in metaData[\"source_x\"][metaData[\"source_x\"].notnull()]:\n",
    "    sourceDic[s] += 1\n",
    "sizes = []\n",
    "explode = []\n",
    "labels = []\n",
    "for s in sourceDic:\n",
    "    sizes.append(sourceDic[s])\n",
    "    explode.append(0)\n",
    "    labels.append(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAWQAAADuCAYAAAAOR30qAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADl0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uIDMuMC4zLCBodHRwOi8vbWF0cGxvdGxpYi5vcmcvnQurowAAIABJREFUeJzt3Xd4VFX6B/DvuVOSKamT3gklEEAIRQGBIKAuGIqKgOXnWlfB3VVXdzfqunaNXVFRbGsBC1gxIliAgPQy1KGT3klPJpO5M3N+f9wBKaFkksyd8n6eZx4mc9s77Prl5pxzz2GccxBCCJGfIHcBhBBCJBTIhBDiISiQCSHEQ1AgE0KIh6BAJoQQD0GBTAghHoICmRBCPAQFMiGEeAgKZEII8RAUyIQQ4iEokAkhxENQIBNCiIegQCaEEA9BgUwIIR6CApkQQjwEBTIhhHgICmRCCPEQFMiEEOIhKJAJIcRDKOUugJD25BhFNYBkAD2crwgAGgDadl4a58sBwOx8tQJoBlDnfNU6X4UADmVnqGrc+HUIuSCMFjklcskxigoAAwBcBCl0U/FHAMeje3+DqwVwqJ3XwewMVWM3XpeQs6JAJm6TYxTDAYwAMBLAKAAXA9DLWtSZOIB9ANYAWAtgbXaGqljekoi/oEAm3SbHKMYDmAQpfEdxzvswxpjMZbmiEM5whhTQ+2Suh/goCmTSpXKM4mAA0zjnUxljQ+Sup5uUAvgKwGIAG7IzVPQfEekSFMik03KMYgaAmZzzWYyxHnLX42ZFcIZzdoZqk9zFEO9GgUxckmMUowHcyR2Om5kg9Ja7Hg9RAGAJgC+yM1TbZa6FeCEKZNIhOUbxYrvNdp+gUMxgjKnkrseDbQPwJqRwtshdDPEOFMjkvJxjgmfabeI/FEpVhtz1eJljAN4H8EZ2hqpM7mKIZ6NAJmeVYxRjHQ7HXHDHHEGhNMhdj5ezAvgMwIvZGSqT3MUQz0SBTM6QYxTDbFbLYwqleg4TBLXc9fgYDiAXwGPZGSqj3MUQz0KBTE7IMYoaS3PjQ6pAzQMKpUordz0+jgNYCODh7AxVidzFEM9AgUyQYxQVbS1NcxQq9RNKdUC43PX4mVYArwLIyc5QNcldDJEXBXI3YYytBvAg53xrB45ZBuAGznl9txV2mifX189iTHhRFahJdNc1SbsqATwO4L3sDJVd5lqITCiQu8nZApkxpuCcy/4f3GNrqvsIguLzAF2Qrz5N5632AXgwO0O1TO5CiPvRfMgnYYylMMb2M8Y+YowdZIwtYoxNZIytY4wdYoxdzBjTMcY+ZIxtZowZGWPTnMdqGGNfMMb2Mca+hTQd5PHzNjPGXmaM7QQwmjF2gDGW5tz2OWPsTuf7AsZYBGMshzF2z0nHP84Ye7ArvuPd/1st/Cv34PNqjW4PhbFH6gfgxxyjuCjHKIbJXQxxL7pDPgljLAXAYQAZAPYC2AJgJ4DbAUwFcCsAEwAT53whYywUwGbn/ncBGMA5v40xdhGA7QBGcM63MsY4gFmc88XO61wO4EkArwO4hXP+J+fnBQCGAUgE8BrnPNP5uQnAlZzzTs06dv9XOzP0hqjFutCIXp05D3GbMgB3ZGeofpK7EOIeNEH9mfI557sBgDG2F8BvnHPOGNsNIAVAAoCpJ92xBgJIAjAWwDwA4JzvYoztOumcdgBfH/+Bc/4LY+w6AG8BGHR6AZxzI2MsijEWByASQF1nwvi+JUaFOlD7UkRy778qlCr639x7xAFYlmMU3wPwj+wMVbPcBZHuRU0WZ2o76b3jpJ8dkP4BYwCu5ZwPdr6SOOfnm47RcnK7MWNMgPSrqRnA2X4tXQJgBoBZAL7s+NeQ3P/1zuHBkbGHwhNS76Mw9lp3AtiVYxTHyl0I6V4UyB23AsDfjs/ryxg7/ijxGgA3OD87vgrG2dwPqfPmBgD/O8ucEF8CmA0plJd0tMj0zCx23xLjU5FJfTZoQwz+NgObL+oBYFWOUXwlxygGyl0M6R4UyKdKAHBG+ypj7P2TPn8KgArALmeTxlPOz98GoGeM7YPUPrytvQswxvIA/AXAA5zztZCC/D+n78c53wsgCEAp57y8I1/iqn+8EDX5/hfWxfQa8B9BqVR05Fji0QRI/5jn5RjFOLmLIV2POvVO4uzUy+WcD+jkeWQb2nZTznOjU4bf/LU+PCpKjusTtykDMD07Q7VF7kJI16E75DMpncPd9jHGvmKMaRljqxljwwCAMXY9Y2w3Y2wPY+z54wfJPbQtPTOL3fP6mPtGjPn6ZxW2euMySaRj4gCsyTGK18tdCOk6FMhnSgMwn3PeD0AjgLnHNzhHPTwPYDyAwQCGM8amOzfrAGzinA/inOcB+CuAjxhjswGEcc7fO+06XwKYedLPM+Fi592gzNDAy64p+u6iS82vBGi4JkL7tM7WepQew/V9gQA+yzGKz+YYRfpH2AdQIJ+pmHO+zvl+IYDRJ20bDmA157yac24DsAjScDegnaFtAHZDGtp2x+kX4ZwbAUQxxuIYY4Pg4tC2YVeEhV91e8yvg8eopgoCGACoAxxanXinxWFvsXX0fMQrPQTguxyjGCR3IaRzKJDPdHqj+oU2srt9aNu4mZG9pt4Vu6HHAN2lp2/TB7VECrV30oTo/mMqgPU5RpHmJPFiFMhnSmKMjXS+vwHA7ydt2wwg09kGrABwPYC8s5ynW4e2zbiq97Arro9eGdtD0+ds+xgijiaJVc8WduS8xKsNALA2xyj2lLsQ4hoK5DMdAHCPc/haGKThbAAA5/CzbACrID1SvY1z/v3pJ3B25t2BbhraNisrbcKj/Sf9OHH3KAV3nHuYTJRhaaK1/qeKCz038XrJkDr7+spdCOk4GvbmRSalpbGoSM1t/xw57pVEfVgwAOxRFRaa/rQz+VzHiVbBXOtYaFdqUqmN0X9UAbg8O0O167x7Eo9Bd8heYlJaGksMCZnx8IiJLx4PYwAYICYn9/q1X8G5jlWpHVq9eEcbdfL5lSgAv+YYxf5yF0IuHAWyF5iUlsai9PpZ948ZMz8mKOiMDsIhrb1TEtf0LDjXOXRB5gihjjr5/EwkgN+o+cJ7UCB7uElpaSw4IGDaA2PGvBoXHBxxtv1GNvRPid6YdM4OPIPhaJJY/TR18vmXaAArc4xib7kLIedHgezh1ArFlQ+OHTsvOSws5nz7jqkalGQwxp5zLHNUeG6iWP8jdfL5l1gAy3OM4ln/QSeegQLZg01KSxt77+jR8/pERl7Q2FKBMTaueGh8sCmi9Kz7CBAMmmeCba2HG7uuUuIFUgF8k2MU1XIXQs6OAtlDTUpLG/rnoUNfHhof36FfNRVMECYeuiRadzjsrHfBUiffX6zUyed3xgBYIHcR5OwokD3QpLS0XpMntjw3OjXBpXY/paBQXr53ZFhgcdCxs+2jCzJHKOruoE4+/3NLjlH8t9xFkPZRIJ8HYyzGuXjpEcbYNsbYMsbYvYyxHSe99jDGOGOsH2NsHGMs19XrTerXKzpjUMtTd91VNs4w7S11na3GpfZetaAMuHzbaJ26QlN3tn3CDflJYhV18vmh53KM4vTz70bcjQL5HJyrgnwLaUKhnpzzoZAmctl+0hJOgwEsBbDoApZyOqep45kuKqXitX/cW3GNWs1VmiCzJmHmW1HVisMuhaZGodJM3DhGpawJOGt7cZSBOvn8EAOwMMcoDpa7EHIqCuRzuwyAyDl/5/gHnPOdzsehAQCMsbGQps6c287xF2zqeKZgDLf/576WSyMM9hMdL0qVQ+g1Y2FyTdi6Qu7CY5V6RaB+wtoxXGhQmdvbTp18fksH4Icco3je0TvEfSiQz20AzrIUEwAwxkIBfATgz5zzzgbalNuuxf/1Tka7IypSr/gluaXPN2Wi3W7t6IlDFNqQy1aNbmVmhaW97X908jVTJ59/SQDwodxFkD9QIHfOOwA+PWn+ZJdMHc/Sh6Tj9qxMZJxrv/ghu+OFSz9oMtssHQ5/gyLIMObnSxthEcT2tjs7+Tq0dh/xCZNyjGKnfrsjXYcC+dz2Ahja3gbG2J8hzaz1VHvbL9TU8Sw0RI+/3/dnjFYocN4FScOTywwhWW8o6211VR29VowiNGrkihHHYEO76/2FGwoSbdVPFnT0vMTrvZhjFM86jStxHwrkc1sJIIAx9pfjHzDGLmKMZQJ4FsCNzpVDXDJ1PFMAuO1fd2BCaBBCL/Q4bUiLNv66Nw3VKOjwCiOJQkTs0J8uLoe9/fboyPBlSWIddfL5GS2kTj6l3IX4Owrkc3B2ol0NYKJz2NteAM8B+C+k/xN/c9rwtzEdvMTE6RMwbWAf9OpobUq1XdFr1keJx4I3F3a0r68nYhIGrhhSzB1nHicIEAzaZ0JsrYeok8+/DAfwqNxF+DuaD1kmU8ez1MhwPP3mo5imCYC2M+cq3jykRHvkqmiloGhvVZKz2hlwtPDAFXvanUu5pUl7zKxbGioo9HTX5D9sAEZnZ6g2yV2Iv6I7ZBlMHc8CAPzl/j9jSGfDGAASL96ewC/+uKHV1tbckeMGtaUm91iVVtDeNqmT73bq5PMvSgCf5hhFndyF+CsKZHlMmjACGQN6I62rThjRsyhC/6f5aBAbqzty3PDmtJS4dT3affAk3FCYaKt6gp7k8y+9ITXJERlQILvZ1PEsKTAA19x6DYZ39bn1hgZ97HXzwo7xkpKOHHdpzYDkyK3xRe1tizL8lGSt/4HulP3LvTlGMVXuIvwRBbIbOUdV3DJnNvoF63HGyh9dQRVgU/aY+X5CtXZHwYUewxhDZtmQxLBd0WcEORPAIjTPhVInn18JAPCi3EX4Iwpk9xqTEI2BY4ahW+cQEASg15TvUuoTlhfbHY52xxyfcQxj7LKC4bFBB8LPuBtWqR0avXgXPcnnX67JMYqZchfhbyiQ3WTqeBYMYPac69FHqYBbRi4kX7ox0Tbk0xqLzdruPBYAcM9336HXCy9g5FtvQckExcT9IyM0+cEnHjrZtKwWT8wy4cXbt0bMvzHVUX5wJwCgua4a79w2Dq9dNxh7V31/4nyf3H8NGqtpVk8f8UqOUaSMcCP6y3afyQN7I6p/Lwx050Wj0vKjtJe/bWsSm2va237D4MH46qabTvysEhSqK3ZdGhxQqqsFgIh4NR58rw8eX5yOa/5qUC95JKsNAHYu/xKXXHsn5n6yHus+ewMAsC8vF3FpgxEcGdf9X4y4wxAAt8hdhD+hQHaDqeNZNIAr7pyJgYIA5u7rB0XVBUddOy+oxlFxxtJOl6akIEyjOeWzAEEVePmWMQGqKk19z0F66IKlG/rUgTq0NtYGWOuWliuUKoiWVtjFNgiCAnabDes+ewNj//yge74UcZdncoyiXu4i/AUFsntcPe5iRKbEd/yJvK6i1ljVyTMXxFUH7LmgYWxahVo3Yf1oQVGnOjG2ed13NRgwKhgR2pzQ/plDG015P+CDOZMw7rZ/Y+OSd5Bx1Y1Qazo9rJp4lhgA2XIX4S8okLvZ1PEsFcCIG6d0b0fehVAoOHt2y1fJPV582jHirbfa3ae+tRU3fvEFRs2fj+kffBocu7ivQ2hSmrevrMP375Th8M5m7FlXq4kM/Kd486uLbMFRcQiOjMX+NT9iwMRr8M1Td2PRP2ehcOdGN3870o3uzTGK4XIX4Q8okLvR1PGMAZg1YQTCog1IkLseALhlOvDrxzbBpq63tdnF1tO3v7x2LQbGxGD93Ll45+qrkfPLmuCIhX3aPn2qiE+9OxaPLOyH3z6vgi6o1WBaemV9XNpgbP72Q1x2ezZ2Lv8SyYNH4bonP8RvCzo1CR7xLHoAf5O7CH9Agdy9+gJIm3GlezvyzmXscCA8FAjQiMqAyxZYm8WWU9bcO1BdjbE9egAA+kRG4mhtLf6+5Iew6X0HmAMDlHab6IAgMNhtHNuW74/oPbC0rLGqBKnDMiFazGBMAMAgtp2R9cS7/Z0eqe5+NLlQN3HeHf87LP2qjGFX/2XEpKBH9L2C93jEr30FpUDW3cCeH4AZf1PYV29Qs4bWNiFKp0P/mBi02WyYnp6OQbGxmPj++9Cp1UgMCUFhQz23CXZ2z6upKDtigUanwO7fGzDqpseq4gbdE9VcW4VP/zEDluYGXD7nMQyYcI3cX5V0rQeyM1SvyF2EL6NA7iYTL4sYqITlv0PvXdE3KPniAZxzqBs2lY4PeFSZEZ4XLWdtJwcyANhtgiP/+1nFkba05EaLBdnLl2NXeTnSo6Nx6NgxvD5lCi6KjQUAHGRlxb+P3pDw3sMFbM5LqVj8cgma6uz24bPnWXpeMpvuoHxbEYDU7AzVBT1sRDqOmiy6SaVj0JTm0CsG6hKG9Aekx5PF0BHxKzS/RD9fubsqr+q6UodD7iolCqVD6HXt58m1EWsK9QEBfP706fh9zhwsuPpqHGtpQUrYH0959+FxiWseEpsm3xaDLcvr0GuwHnc8k6zIe+9varutud3loYjPSII0PzjpJhTI3SA9MyvGDk3vQdc8UCsolGeMO+bBaVEbghbFP1+bX5dbPrfIald6RDT3mLAyuTzxy4rmtrY2APhk+3aMSk5GcGDgiX2O1NQAzULw5PqLC6wWB5gAAAzgdpWy/jZaacT33Sd3Ab6Mmiy6QXpm1mylOuCKmU9/fL1SHRB4vv0dlrrmnub5x7KiXo7TqZrV3Vnb9Q8AqzcDx+qBaAPwxF8B0TlDxd2zgQ1G4MYHFA5YgtE/Olp4c9o0hJ704Mgtixfj0QkT0NNgwI/YVvToNyuTWpvtmHp3LIZOCENl9ZUFyqgnUrrzOxDZDcvOUJ11NXbiOgrkLpaemRUE4OUBE68NG5J104yOHOsQzZbYxk8rphqeijJoqmR9wqK1QdtamXtHY5gy/Jzt3asjjMVVI4sTj//MHeCVjQ9VqMKmxXZ/lUQm72RnqObIXYQvoiaLrjcEgCpl8KgBHT1QUGkDKw13pbxrz1fPL/28sLi5Z4OrRdjtQMY1Uufd6V75CEjPAi6aBky4FSh0PlB9IB8Yeq30+Y6jZk3CzLciyvnhomkffwyz1drudcZWD04I3RZzoqmCCWAGbU6YzXyApuv0XdflGMUOLRdGLgwFchdKz8xiAMZrQ8JbQ2OTe7t6HqZQKRvDr01eyPYGv1a2onhf/dBjHT3H658C/c4yxXhGP2DrEmDX98CMK4B/vSR9vuBL4PWHgWULgJf+ByhVdsUvtoVJE4ZpjmlUqnZ/lRIYYxNKh0XpdhlOTF6kUvPAIPvdInXy+SwDgMvlLsIXUSB3rWgASf3HX50gKBSKzp6MCQKzhF2W+H3AhogXyzeVb6r50wWt3FFSAfyYB9xxlgaTyy4BtM5m4RGDgJJK6b1KCZgtgLlVel/fCPywCnjkcVNEc6/vykS7vd3bZAUThCvzR4So94U0Hf9Mq281KOtvpU4+33W93AX4IgrkrjUUgCM+fehFXX1ie2hG7Crt0ticqv3Hfq28ucTuYGdt/L/vOeCFB6WJ6s/ng6+BSWOk9/fcADy7APjzQ8DDdwFPvS39KQhAwrCd8WzUh01mm6WpvfMoBYVy8sFL1cIR/YlH9MINxYm2qv8WdPCrEu8wPccoas6/G+kICuQukp6ZJQAYH56Qag2KiEnutgsFpUZsDX4/4fn64sZvyx4otNgCTlnFI3cVEBUODO1//lMtXAps3QP883bp56Q4YPUnwIYvAG2gdKfdLxX4v38Bs+4HanipIWTym4p6sb6qvfOpBWXAVbtHA0WaE3fSUYafk8W672hNPt+jBzBF7iJ8DQVy10kBEJ6eOaU3Y90/5bGgiQo5EPZc8ivNpdaFpTkFDW2hFgBYZwSWrgJSJgCzHwBWbgJu+teZx/+6HnhmAbB0PhDQzkC7R14Dnr4XmLdQavp44UHgifmANqxZG3fdm+HHUFTcXl0ahVrzp21jbKgIEIHjnXzPh9nM+13uoCQei5otuhgFcte5GIAtps9Fbp1ISAgI1paE/yPlLWuR8F7J+wX3zolvLlkNFPwGfPEyMP4SYOELpx5jNAF3PQ4sfQuIMpx5zrzNQFwU0DtFak8WBOlldjZGqAJsyp6zPkw8pt9a0N6wyWBloHbChtFWXqOyAcc7+ebYqJPP50zKMYohchfhSyiQu0B6ZpYKwNjQ2ORWbUh4lBw1CMpAdY3h5pT/OQ5p3ij9tuhoY/9TZnH77zxg6Urp/T9fBJrNwHX3A4OvBqbO/WM/zoGn3wEedY4y/ctM4N5ngavuBh687dRr9rwqN6Up5ccSm8NxxuKnBqVONyZvVBtvVNoB6uTzUQEApsldhC+hB0O6QHpmVjqABzOybgodOPFaj3jWn3MOdf3G0gmBjyoHh6/p1smMqg+nVDs23aANVKrPmFwo31pj3jx5QwDTOBQAUFl9eYEy6qmU7qyHuNXH2RmqW+QuwlfQHXLX6AfAHtWjXw+5CzmOMQYxbGT8cs2v0c9X7qxcU3Vtt01mFNmrIFJ35Vu8UWw6Y7x0D7VBO2jZcCsXmQMAoiJ+SbbWfUPLUvuOcXIX4EsokLvGEAANobFJHhPIJ+PB/aLXB30e/3zt0dpl5Xd3y2RG+ogGffSMeSHHHGUlp2/rq47W9P0ho43bwRkDi9S9GE6dfD4jOccopshdhK+gQO6k9MysYACxUT36qQK0eo/u4GC6hPBdofOSXmosaVlc9mhBi6jt0k42daCo6jHr3YRqzc6C07cNUiVoUn8Y1ModgFLFA4Psd9vstkbq5PMNmXIX4CsokDuvBwAkDRrpkXfH7RECw4OOhj2a8rq51P5R6esFtZZIc5edWwB6Tf02pT5uRZHd4ThlIvPhimRtwrIBTQCg1VsMqvrbKrvqukRW4+QuwFdQIHdeOgBbZI80rwnk4wS1LrAifE7KAlu++u2ShYUlLaldNiFQ8pgNSWLGZ8csNuspi+tdylODon/uVwcAYYaSBFvVfwq66ppENuPkLsBXUCB3gnMyoSEA6kKjE70ukI9jCrWywTAz+VOYgl4r/al4f8OQDk9m1J7ovoejAycsEBuszae0F2e29Q6LyOtdDQBREb9SJ5/3S8kxit33dKofoUDunDAAhuie/TWqQI3XryfHBIFZwickfqfeGPFi+cayzceu7PS44ZCYmuDoa94MrBIrqk/+fFxD38iwTakVxzv5RLOJOvm82zi5C/AFFMid0wMAIlPSIuUupKvZQ4fErdT9EJNTta/618qbzjmZ0fkE6CwBqbMXRJQp9pwIeIExjK9MjwnemViuVPHAYPtcO3XyebWL5S7AF1Agd04aADE0NsnnAvmEoJ6RW4M/THi+rqjhu/L7C9tsapdWHFYoOes346uYCsNvlTaHgwOAggmYUHBRjP5AbIVWbwmnTj6vliZ3Ab6AArlzUgC0BEXE+G4gOwna6ND9oc8nv9xcZllU+mxBkzWkzZXzpE1cG93S78t6s9jmAACVoGAT9g2J1ORHVEmdfI8UdGnhxF36yl2AL6BAdpGzQy8RgFkbavD5QD5OCAjWFYc/mPKGpRjvl7xbUNUa19zRcyQNPhCmGvt+67G2RisABCgUigk7Lw5Tl4bWRkX8lmyt+4o6+bxPfI5R1MtdhLejQHZdMAA1GLMF6kMj5C7G3QRVYMAxwy0pHzgOa94s/boov6lvfUeOj0iq1sVMe5sVW8paAUCrUKombhmpUVfrGyJ1L1Mnn3eiZotOokB2XSQAHpHcO1ShVPrtgo9MUCqaw6ckfaHYEfJK2cqSXXWjqs9/lEQX0qrqe8P7gUcce5sBQK9QaSasH6MMaA60Bdvn2h22hvZXViWeipotOokC2XWRABRRKX39prniXBgTmDVsdMKywNWRL1QaK3+vnl56IccpVQ425Pol+nz96iY7d/BghUp/Wd5YUc95oLLhtnZXJiEeiwK5kyiQXZcEQAyNTaZAPo0juH/07/rF8c9VH6n5qeLOIptdcd7JjAZftTqousdXLa120R6uCAgb+9tYc3hgZaSt6uECN5RMugYFcidRILsuBYBZF2oIlbsQT8X0iYadIW8lvdBQ0ryk7OHCVlFzznHGaZeY9I5LPhBrrM1ilEITMeqXzPro4NXxYu0S6uTzDtSG3EkUyC5wjrBIAtCi1uqpZ/k8BI0h+EjY48mvmstsH5e+WlBnMbSebd+4nhWBhslvsyJrZVu8oIu+eMXYqojA10JtLaYOdRoSWSTKXYC3o0B2TQAALQBRrdF6/SPT7iKodZry8HtS3rYVKt8p+aSwzJzS7mRGIYYWZdqsd9UHHQfNKSw4fthvI2uCqJPPG4TkGEWl3EV4Mwpk1+gASA82BFIgd5SgUKvqDbOTP+b79K+XLis+2DC45vR91Go7G379Z9pDug1NvR1hicPWDWpW1lMnn4djANpZNpdcKApk1+gAcABQqgMpkF3EBIXQGj4x8Rv1ZsNL5RvKttRcfsZkRsOyVgSVpfzQkNYWGTfcGG23VT1UIEOp5ML53Zj8rkSB7JoTIaxQqQLkLMRX2EKHxv2m/TEmp8pU/XPp7Gq7nZ3Ylj5ie0jb8I8tac3RhqGmY7DWLr6gIXVEFuFyF+DNKJBdowXAAvUhasYEdt69yYUL6hW5PfyTyOfr8hu/PDi3pU1UcQCI71UYpPvTW4q+9ZG6QftWtFEnn8cKkrsAb0aB7JpAAEwTHEZ3x91E0MUF5ye+pnuxvtD2wd7HzHWtwTwkvF4Tf83rYWl1WlXv3fOOUSefR6JRR51AgeyaQAAsMCiUArmbKfURqurUR7TzW/P5vD2vtVVbI9Hn2gWJA611ijjjswWcd/kC2qRzKJA7gQLZNXoANoVSpZC7EH+h0AQJ5p5zAz7mB5QvHfmiIXDUwbBR2vWBIXvfOSR3beQUFMidQIHsGj0Au90mujRZO3GdoAqAI+GakC+FbaHfxb4q9NWsF1Sla6mTj/gEGsTtGiUAbhetFMgyYYIAR/iwhM3hC+GoK6hmnIMx6l/1ABa5C/BmFMiusQFgdpuVGjA9gBCWQhM8eQ6XVpIhEmqycI0UyCI1WRByGgrkTqBAdo0IQLCLdIdMyGmoyaITKJBd47xDpjZkQk5Dd8idQIHsmuOBTHfIhJyKArkTKJBdYwPARKuF7pC+NZgXAAAT0ElEQVQJORUFcidQILtGBCA4bKLDbhPp8V1C/kBtyJ1AgeyaE3fG1taWdidZJ8RPVcpdgDejQHaNBc4J6q3mZgpkQiQiAFr/sBMokF3TAGcgW5obKZAJkZRmZ6ioo7sTKJBdcyKELU31FMiESArlLsDbUSC7phHOvztzQ22DzLUQ4ikokDuJAtk1ZkhD34Tm2iq6QyZEUiR3Ad6OAtkFprxcDqAWQEBjdRkFMiESukPuJApk1x0DEFhXWkBNFoRIKJA7iQLZdZUAAswNNW3W1pYmuYshxAMUyF2At6NAdl0lADUANNdW0dhL4u+aAByRuwhvR4HsugoAHAAaKoppCSHi77bQGOTOo0B2XRkABgDVhQfpDpn4u81yF+ALKJBdVwPpEWpVyd5tFMjE322SuwBfQIHsIufQt8MAgpprKlrbWprq5a6JEBlRIHcBCuTO2QdABwBNNZXUjkz8VUl2hqpc7iJ8AQVy55x4Mqm+ooiaLYi/orvjLkKB3Dl/dOwd3U93yMRfUYdeF6FA7px6AC0A1Pnb15bQ6iHET62XuwBfQYHcCc6OvQMAgm1Wi72hsjRf7poIcSfOeR2ADXLX4SsokDtvOwAtAFQdNR2WuRZC3IoxtiI7Q0WL/XYRCuTOOxHCR7asOiRnIYTIIFfuAnwJBXLnVUOailNbU3S4wdxQS4s8Er/AObcDWC53Hb6EArmTnO3IGwGEAUDV0X375K2IELdZk52hqpG7CF9Cgdw1dgNQAMDRrXn7Za6FELdgjH0ldw2+hgK5axwBYAWgKtm7pdLS0lgnd0GEdCfOuQPAN3LX4WsokLuAKS/XBulppQgAqDxs2iNvRcTd1n32Bl67bjBenTEIvy+aBwBY9mo2XrlmAF6fOQSfPjADre1Md1JdcADzZg878Xp8jOHE8T+9/hBenzkEix+99cT+xh8Xndgus3XZGaoKuYvwNRTIXWcrABUA7F35zTbOHVzmeoibVBzegy3ffoC5n6zH37/Yhv1rl+FY0WH0GjEB9y7egXsXb0dEUm+s/vD5M46NTEnD37/Yir9/sRV/XbQJqkAt+l82DZamBpTtl45VqNSoOLQboqUV25Z+gpEz58jwLU/FGPtY7hp8EQVy1zkIoA2A+ljhoYaGihJaPcFPVOfvR+KAi6HWaKFQKtFj6BjsXfkd+oy8HAqlEgCQNPASNFSd++n6w5tXwpCQirC4ZDBBgN0mgnMO0WKGoFRhzaevYOTsuVCoVO74WmflcDgaAXwmaxE+igK5i5jyctsArAIQBQBHtq7eKm9FxF2ie/ZHvvF3tNTXwNpqxoHfl6OhsuSUfbZ+/xHSRl15zvPsWrEYF105CwAQoAtC2qV/whvXD0dQRCwC9SEo3r0F/S+b1m3f48Lx/2VnqFrlrsIXKeUuwMf8DmASAOxb/cPBgROvbVRrdMEy10S6WVRqP2Te8k98OHcy1Bod4tIGgQmKE9tXvf8cBKUSgyffcNZz2EQr9q3JxZV/e/rEZ5m3PIjMWx4EAHz95F24fM5j2PLthzi08RfE9B6I8Xc83H1f6iw451wQFPPdfmE/QXfIXciUl1sG4BCAcIfdxssO7DDKXRNxj+HTb8XfPtuEuz5YCU1QKCKSewMAti39BPvWLsOspz8BY+ysxx9ctxxxfTMQZIg+Y1vZfiPAOSJT+mD3L1/jhuc/R23xURwrcv+DoQ67LS87Q3XQ7Rf2ExTIXW8FgCAA2P3L19u4gzr3/EFzbRUAoL68CHtXfYfBk2bjwLoVWPPxS7j5tW+g1mjPefzO5V9ikLO54nQ/z38Cl899HHabCIdDmjaCCQJEi7lrv8QFUChVHjHEw1dRk0XX2w2gFUBAXWl+U1150cHw+JQ0uYsi3WvRg7NgbqiBoFRh6r/nQRMUiqXP3we72IYP50wCACQOvARXP/IWGqvL8PWTd+PWN5YCAKytLTi06Tdc/ciZLQF7V32PhPQhCI6MAwDEpQ3CazMzENN7IGL7DHLfFwTgsNsqBYVyqVsv6mcY53QD19XSM7OuhdSWXJI2ZnLqJdfe+X9y10RIZ3GH4/GHhgY8IXcdvoyaLLrHOkh/t+zA2mVHm2oqi+UuiJDOcDjsrUwQ3pa7Dl9HgdwNTHm5FQBMcD65t3flt6vkrYiQznHYbG9lZ6iq5K7D11Egd5/vIa1IzQ6uW5HfWFVWIHM9hLjEbhNblOqAZ+Suwx9QIHefw5A6+KIAYNcvS1bKWw4hrrFZLS9nZ6jOnIiDdDkK5G7inCf5GwAaAOzoltXF9RVFtMQT8Sp20VofoA06cxIO0i0okLuRKS83H8A2OO+Sd/70Jd0lE69iE61PZ2eo3D/g2U9RIHe/7wEEAmCFO9eX15bk0wT2xCvYrG2VAVr9G3LX4U8okLuZKS+3CMBmADEAYPxx4UrucDjkrYqQ83PY7f/JzlBZ5a7Dn1Agu8f3ANQAhNJ926uL925ZL3dBhJyLtbXlgFqj/VDuOvwNBbIbOCcdWgsgFgDWLZqXZ2lurJW3KkLa53DYHTbRekN2hop+k3MzCmT3+RqACEAjWsy2HT99lit3QYS0p7Gy9KMnM6O2y12HP6JAdhNTXm4DgE/hbEs+uG5FftXRfTvkrYqQU1maGysFpUr+NaL8FAWye20CsAfOUP594Ws/i22tLfKWRIiEOxy8uaby1mevSKKOPJlQILuRKS/XAekuWQlA3Vxb1bov78cVMpdFCACgsbrs25emp/8kdx3+jALZzZwTD30FIA4AdixbtJue4CNys5qb622i9Va56/B3FMjy+A1AMQADAKz99LWlYpsMyz8QAoBzjsZjFXNfnJLWKHct/o4CWQamvFwRwP8gLfWkrCvNb9qxbNG3tFgAkUNtyZGvXprW73O56yAUyLIx5eUeBbAUQCIA7MvLPVyyZ8s6easi/qaxurwof9taWtHGQ1Agy2spgP1wjrrI+/illU3HKorkLYn4C2urubVwx/rpXz3xF4vctRAJBbKMTHm5NgDvAnAA0DtsomPV+88tsbaam2Qujfg4h8POi3ZueGDRv2Yb5a6F/IECWWamvNwaAG8DiASgrK8oat701YLFDofdLnNpxIcV7968aP0Xb74jdx3kVBTIHsCUl7sb0mT2iQCQv21NyYHfl9N4UNItqo7u25H3vxfucC6icE6MMTtjbAdjbA9jbAljTOv8nDPGFp60n5IxVs0Yyz3ps0mMsa2MMRNjzMgYe7l7vpHvoED2HLkAtgNIAIAt37y/rcS0bYO8JRFf01hdXrFzxeLJprzctgs8pJVzPphzPgCAFcDdzs9bAAxgjGmcP18OoPT4QYyxAQDeBHAT5zwdwDBIy5qRc6BA9hCmvFw7gA8A1MK5WvXK9575ufKIiea7IF2ipa66bsdPn2f99u7T5S6eYi2AXif9vAzAVc731wM4eejcvwA8wznfDwCcczvn/G0Xr+s3KJA9iCkvtxnA6wAUAELAOX6Z/9jS2pKjtMoI6RRzY13TxiULbl/26r+3uXI8Y0wJYBKkhXuP+wLAbMZYIICLIM3VctwASMuXkQ6gQPYwprzcUgAvAdAD0DvsNr7ijf981VBZmi9zacRLWVoazRu/nP/PUtO271w4XMMY2wFgK4AiSL/FAQA457sApEC6O17WFbX6OwpkD2TKyz0C4FVIj1ZrxLZW+4o3Hvmiubaq9DyHEnIKa6vZsmnJu/8t2bv13QvpxGvH8TbkwZzzv3HOT58JbimkG4jTn/TbC2CoKzX7MwpkD2XKyzVB6hSJARBgaW6w/vzWY4taG+uqZS6NeAmxzWLd8u37OYU71r3qYhhfiA8BPME5333a5y8CeJgx1gcAGGMCY+zuM44mp6BA9mCmvNxtkH5FjAegaq6paP11wVOfWloa62QujXg4u2i1bVv68bwjm1c945z2tVtwzks45/Pa+XwXgPsAfM4Y2wdpHvDU7qrDVzCa0MbzpWdmTYLUTlcIwB4SnaCbOOexG3WhEbEyl0Y8kK3NYt2W++l7B9Yu+4cpL5cmm/cidIfsHZZDWrk6GYCyobKkZdnL//yoobLkqMx1EQ9jaWlsWfPJy/MPrF32IIWx96E7ZC+RnpnFAEwBMAPSAPw2hUotXHHPU9MjU/oMlLc64gmaa6tqV32Q835daf6TprxcWhrMC1EgexFnKI8FcBuASgBmMIbxdz5yRUL60JHyVkfkVFuSX77qg+deaamrftOUl0uzt3kpCmQvlJ6ZNRjA3wA0AGgEgJGz7xnZ65IJVzDGZK2NuF/ZgZ1HV3/4/BO2ttbPnDMIEi9Fgeyl0jOzegP4BwAbgBoAGDz5hgEDJlw9TVAolbIWR9zmyOZVu9d9Nu/fAJZ349A24iYUyF4sPTMrHsCDAAIhNWEgPn1o1Kjr/3qdJig0QtbiSLeyi1brjuVfbNz727f/NuXlbpS7HtI1KJC9XHpmlgHA/ZBWsS4GwAN0warLbs++Kiq13yB5qyPdoammsmrtxy+vPFZ06AlTXi7Nc+JDKJB9QHpmlhbAjQDGACgDYAGAIVNuHtQvc8pVCqVSJWd9pGtwzlG4c8Oe9Z/NW2Gztr1uysstlrsm0rUokH2EcwTGpQBugRTIxwAgNm1wxOgb/z5TExwWKWN5pJPENkvrlm8/2HB4469fAFhkyss1y10T6XoUyD4mPTMrAcA9AKLhbMJQa3TKy+54aHJ0z/4Z8lZHXFFfXlS6+n8v5DVWlb4JYCN13vkuCmQflJ6ZpYH0qPU4nNSE0f+y6X0GXjHjKrVGFyxjeeQCOew228H1v+zc8u37P3KH4x1TXq6rE8sTL0GB7KOcTRgjAdwKQARQBQCB+hD1pTfdOz4ubdDFjAk0aNlD1ZUVFqz7bN722pKjXwH4pgNLLhEvRoHs49Izs+IghXIfAOVw3i2nDBkdP3TKzZN1YZFxctZHTmW1mJt3r1iyee+q7/YDeNeUl7tT7pqI+1Ag+4H0zCwFpBEY1wNgkIKZM0Fgw6bdmtFrxMQJqoBAraxF+jmHw24v2rXRuGnJgoNtLU2/AvjalJfbKHddxL0okP2Ic8zybAAXQ1pMtQEAdGGRgSNmzRkX2/uiYYJCoZCzRn9UW5J/eMOX83fVFB8+DOBDU17uAblrIvKgQPYzzrbldAA3QxqJUQ6gDQDCE1KDh0z5v0tjeg0cSsHc/eorio7sWrF4X4FxXTmArwGsoikz/RsFsp9Kz8xSQxqFMQPSKtcVkDr/EBaXEjRkys2XxvYZOJTmxehanHPUlRUc2LHs890le7e0AFgLqdOOVoEhFMj+Lj0zKxTABAB/grRgwYlgDo1J0g+ZevOo2D6DhtHTfp3DuYPXFB0xbf9x4d6Kg7taIS0C+rUpL5cWGSAnUCATAEB6ZlYIgPEAJgFQQgpmKwAER8Xrhk65eWRMn4syqPOvY7jD4aguOLB729KP91cXHLAA2A7gBwAF9IAHOR0FMjlFemZWMIDLAEwGoMJJwaxQqYX0cVPTUoaMzgiNTuzFBBrHfDbmhtqqUtO2Hbt//bqyuabSDmATgGWmvNwiuWsjnosCmbQrPTMrCFIb81UAAiCNyKg/vj0svkfQgPHTB8f2HZwRqAsOk6dKz2KzWlqrju7ffWDdT6bi3ZsdkIYY/g5pruIymcsjXoACmZyTcya5gQCuBNADgAPSU3/Sk2OMofeIy1N6XTI+Izw+ta9CpVLLVqwMuMPhqK8oOlxg/H2XafUPtXbRqgbQDGAlgHWmvNwqmUskXoQCmVwQ53C5WAAjILU16wCYIa1W4gCkJo3UYeOSEvoP62VI7NlbGxIeJVvB3cjaam6qLy88UnFo95FDm36tbqmtDgDAAWwFsAbAAVpKibiCApl0WHpmlgpAP0htzccnwTcDqANgP75feEJqcOqwcb2ie6b3Co1JTFWo1AHur7bzHHabrbG6vLC64MCRol0bj5SatpkBhEEalVIM4GcAO015uU2yFkq8HgUy6ZT0zKwwAH0hPf3XH9KYZg4pnE8sRS8oVUKPIWMSonv2TwiNTYzTG6LjPLXtWWxrbWmpqy5vqCwrrzy8p/DIllVlosUcAuB4c0wZgM2QRkyU0mgJ0lUokEmXcT5s0gNSMF8CIBJSx5YZUqfgKU+h6cIiA+P6ZsSEJ/SIComKj9KFRUZpgkMjlOpAjTvqtdtEq6Wp/lhLfU1107GK6vqywuqygzvL60rzWwCEAAhy7mqGFL47ARwx5eXWn+2chHQGBTLpFs42ZwOAXgCGAkgDoId09wxIIdcC5+xzJ1OqAxUhMQn64IhYvS4sUq8NNQQFBoXoA3XBerU2SK8KCNQAYGAMABgDAxikIXiMMQbA4XDYxVZzi7W1uaWtpanF0tLYYmlqaDE31La01FW3NFaXNzfXVraCcyWk9nA9pCYI7nwdBrAFwEEAZaa8XEc3/VURcgIFMnELZ0CHQFqMNQlAbwApkNpijw8REwDYIN1JWyGN5LA6t7tCgDSWWn3an8x5TgHSPwjFAA4AKIA0t0c1dcoROVAgE1k5VzeJAhAB6S7V4Hwf7nyFQnpy8Pid64Vg+CN0GyE1l9Q5XzWQZrqrdr6aqA2YeAoKZOLRnHfWAZDC+vhj2+wcf9ohNYW0ALBQ2BJvQoFMCCEeQpC7AEIIIRIKZEII8RAUyIQQ4iEokAkhxENQIBNCiIegQCaEEA9BgUwIIR6CApkQQjwEBTIhhHgICmRCCPEQFMiEEOIhKJAJIcRDUCATQoiHoEAmhBAPQYFMCCEeggKZEEI8BAUyIYR4iP8HXeIqMZylUPsAAAAASUVORK5CYII=\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "colors = ['gold', 'lightskyblue', 'yellowgreen', 'lightcoral']\n",
    "plt.pie(sizes, explode=explode, labels=labels, colors = colors, autopct='%1.1f%%', shadow=True, startangle=140)\n",
    "plt.axis('equal')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 4. Publish year distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "yearList = []\n",
    "for y in metaData[\"publish_time\"][metaData[\"publish_time\"].notnull()]:\n",
    "    yearList.append(int(re.split(' |-', y)[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Frequency')"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.distplot(yearList, bins = 50)\n",
    "plt.xlabel(\"Year\")\n",
    "plt.ylabel(\"Frequency\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "A lot more coronaviruses related articles published in the past 10 years."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 5. Has full text distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of articles with full text: 13219\n",
      "The number of articles without full text: 16281\n"
     ]
    }
   ],
   "source": [
    "hasFullText = metaData[\"has_full_text\"][metaData[\"has_full_text\"].notnull()]\n",
    "nanCount = metaData.shape[0] - hasFullText.shape[0]\n",
    "trueCount = sum(hasFullText)\n",
    "falseCount = hasFullText.shape[0] - trueCount\n",
    "print(\"The number of articles with full text: \" + str(trueCount))\n",
    "print(\"The number of articles without full text: \" + str(falseCount + nanCount))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 6. Abstract distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of articles with abstract: 26553\n"
     ]
    }
   ],
   "source": [
    "print(\"The number of articles with abstract: \" + str(sum(metaData[\"abstract\"].notnull())))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now we try to normalize the abstracts to learn the distribution of abstract length and tokens. The following steps will also be the steps to preprocess the abstracts for extracting tf-idf features."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time spent: 2.217min.\n",
      "The number of tokens: 50493\n"
     ]
    }
   ],
   "source": [
    "startTime = time.time()\n",
    "absLength = []\n",
    "word2count = {}\n",
    "for abstract in metaData[\"abstract\"][metaData[\"abstract\"].notnull()]:\n",
    "    ## Remove web links\n",
    "    abstract = re.sub('https?://\\S+|www\\.\\S+', '', abstract) \n",
    "\n",
    "    ## Lowercase\n",
    "    abstract = abstract.lower()\n",
    "    \n",
    "    ## Remove punctuation\n",
    "    abstract = re.sub('<.*?>+', ' ', abstract)\n",
    "    abstract = re.sub('[%s]' % re.escape(string.punctuation), ' ', abstract)\n",
    "    \n",
    "    ## Remove number\n",
    "    abstract = re.sub(r'\\d+', '', abstract)\n",
    "    \n",
    "    ## Tokenize\n",
    "    words = word_tokenize(abstract)\n",
    "    \n",
    "    ## Remove stop words\n",
    "    nltk_stop_words = stopwords.words('english')\n",
    "    words = [word for word in words if word not in nltk_stop_words]\n",
    "    \n",
    "    ## Stem\n",
    "    stemmer = SnowballStemmer('english')\n",
    "    words = [stemmer.stem(word) for word in words]\n",
    "    \n",
    "    ## Lematize verbs\n",
    "    lemmatizer = WordNetLemmatizer()\n",
    "    words = [lemmatizer.lemmatize(word, pos='v') for word in words]\n",
    "    \n",
    "    ## Record length\n",
    "    absLength.append(len(words))\n",
    "    \n",
    "    ## Get word count\n",
    "    for word in words:\n",
    "        count = word2count.get(word, 0)\n",
    "        word2count[word] = count + 1\n",
    "print(\"Time spent: \" + str(round((time.time() - startTime) / 60, 3)) + \"min.\")\n",
    "print(\"The number of tokens: \" + str(len(word2count)))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Distribution of abstract length\n",
    "There are 20 extremely long abstracts. We excluded them from the histogram."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.distplot(sorted(absLength)[:-20], bins = 50) # There are 20 extremely long abstracts\n",
    "plt.xlabel(\"Abstract token count\")\n",
    "plt.ylabel(\"Frequency\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Top 50 mostly frequent tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x140b7ce10>"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x720 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df_word_count = pd.DataFrame(sorted(word2count.items(), key=lambda x: x[1])[::-1])\n",
    "sns.set(rc={'figure.figsize':(12,10)})\n",
    "sns.barplot(y = df_word_count[0].values[:50], x = df_word_count[1].values[:50], color='red')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# II. Article and sentence retrieval\n",
    "Now let's start building the system for article and sentence retrieval. For the first level of retrieving articles, we build a tf-idf vectorizer for all articles based on their abstracts. Therefore, whether an article is considered related to a query is only based on the content in its abstract. The reasons we didn't include all text from the article is that 1. most articles don't have a full-text available; 2. abstract as a high-level summary of the discovery of the article is more information-enriched compared to the full-text; 3. only including the abstract will largely reduce the vectorizer learning time. For the second level of retrieving sentences, we first retrieving relevant articles. Then from the abstracts and paragraphs in discussion and/or conclusion sections (if exist) of the articles build a second vectorizer and retrieve the most relevant sentences. The reason we only take abstract, discussion and conclusion into consideration is that for most tasks in this challenge, the questions of interest are mostly high-level questions, to which the related information is more likely to be in summary sections rather than experiments or results sections. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Preprocess metadata\n",
    "This section only needs to be run once. The new metadata table with the normalized abstracts in the column \"clean_abstract\" will be saved to all_sources_metadata_2020-03-13_clean.csv in the output folder."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "def textNormalize(rawString):\n",
    "    \"\"\"\n",
    "    Function for text normalization.\n",
    "    Text normalization includes:\n",
    "    1. removing web links\n",
    "    2. converting all letters to lower or upper case\n",
    "    3. removing punctuations\n",
    "    4. removing numbers\n",
    "    5. tokenization\n",
    "    6. removing stopwords\n",
    "    7. stemming\n",
    "    8. lemmatization\n",
    "    Input:\n",
    "        rawString: a string contains the text to be normaized. \n",
    "    Output:\n",
    "        normText: a string contains the normalized text where the tokens extracted from rawString are joined by space.\n",
    "    \"\"\"\n",
    "    if rawString == np.nan:\n",
    "        return rawString\n",
    "    ## Remove web links\n",
    "    rawString = re.sub('https?://\\S+|www\\.\\S+', '', rawString) \n",
    "\n",
    "    ## Lowercase\n",
    "    rawString = rawString.lower()\n",
    "    \n",
    "    ## Remove punctuation\n",
    "    rawString = re.sub('<.*?>+', ' ', rawString)\n",
    "    rawString = re.sub('[%s]' % re.escape(string.punctuation), ' ', rawString)\n",
    "    \n",
    "    ## Remove number\n",
    "    rawString = re.sub(r'\\d+', '', rawString)\n",
    "    \n",
    "    ## Tokenize\n",
    "    words = word_tokenize(rawString)\n",
    "    \n",
    "    ## Remove stop words\n",
    "    nltk_stop_words = stopwords.words('english')\n",
    "    words = [word for word in words if word not in nltk_stop_words]\n",
    "    \n",
    "    ## Stem\n",
    "    stemmer = SnowballStemmer('english')\n",
    "    words = [stemmer.stem(word) for word in words]\n",
    "    \n",
    "    ## Lematize verbs\n",
    "    lemmatizer = WordNetLemmatizer()\n",
    "    words = [lemmatizer.lemmatize(word, pos='v') for word in words]\n",
    "    \n",
    "    normText = \" \".join(words)\n",
    "    \n",
    "    return normText"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Read-in metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of articles: 29500\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>authors</th>\n",
       "      <th>journal</th>\n",
       "      <th>Microsoft Academic Paper ID</th>\n",
       "      <th>WHO #Covidence</th>\n",
       "      <th>has_full_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>c630ebcdf30652f0422c3ec12a00b50241dc9bd9</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Angiotensin-converting enzyme 2 (ACE2) as a SA...</td>\n",
       "      <td>10.1007/s00134-020-05985-9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125455.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>2.002765e+09</td>\n",
       "      <td>#3252</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>53eccda7977a31e3d0f565c884da036b1e85438e</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Comparative genetic analysis of the novel coro...</td>\n",
       "      <td>10.1038/s41421-020-0147-1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...</td>\n",
       "      <td>Cell Discovery</td>\n",
       "      <td>3.003431e+09</td>\n",
       "      <td>#1861</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>210a892deb1c61577f6fba58505fd65356ce6636</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Incubation Period and Other Epidemiological Ch...</td>\n",
       "      <td>10.3390/jcm9020538</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The geographic spread of 2019 novel coronaviru...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...</td>\n",
       "      <td>Journal of Clinical Medicine</td>\n",
       "      <td>3.006065e+09</td>\n",
       "      <td>#1043</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>e3b40cc8e0e137c416b4a2273a4dca94ae8178cc</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Characteristics of and Public Health Responses...</td>\n",
       "      <td>10.3390/jcm9020575</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32093211.0</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>In December 2019, cases of unidentified pneumo...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Deng, Sheng-Qun; Peng, Hong-Juan</td>\n",
       "      <td>J Clin Med</td>\n",
       "      <td>1.776631e+08</td>\n",
       "      <td>#1999</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>92c2c9839304b4f2bc1276d41b1aa885d8b364fd</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Imaging changes in severe COVID-19 pneumonia</td>\n",
       "      <td>10.1007/s00134-020-05976-w</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125453.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Wei</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>3.006643e+09</td>\n",
       "      <td>#3242</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        sha source_x  \\\n",
       "0  c630ebcdf30652f0422c3ec12a00b50241dc9bd9      CZI   \n",
       "1  53eccda7977a31e3d0f565c884da036b1e85438e      CZI   \n",
       "2  210a892deb1c61577f6fba58505fd65356ce6636      CZI   \n",
       "3  e3b40cc8e0e137c416b4a2273a4dca94ae8178cc      CZI   \n",
       "4  92c2c9839304b4f2bc1276d41b1aa885d8b364fd      CZI   \n",
       "\n",
       "                                               title  \\\n",
       "0  Angiotensin-converting enzyme 2 (ACE2) as a SA...   \n",
       "1  Comparative genetic analysis of the novel coro...   \n",
       "2  Incubation Period and Other Epidemiological Ch...   \n",
       "3  Characteristics of and Public Health Responses...   \n",
       "4       Imaging changes in severe COVID-19 pneumonia   \n",
       "\n",
       "                          doi pmcid   pubmed_id   license  \\\n",
       "0  10.1007/s00134-020-05985-9   NaN  32125455.0  cc-by-nc   \n",
       "1   10.1038/s41421-020-0147-1   NaN         NaN     cc-by   \n",
       "2          10.3390/jcm9020538   NaN         NaN     cc-by   \n",
       "3          10.3390/jcm9020575   NaN  32093211.0     cc-by   \n",
       "4  10.1007/s00134-020-05976-w   NaN  32125453.0  cc-by-nc   \n",
       "\n",
       "                                            abstract publish_time  \\\n",
       "0                                                NaN         2020   \n",
       "1                                                NaN         2020   \n",
       "2  The geographic spread of 2019 novel coronaviru...         2020   \n",
       "3  In December 2019, cases of unidentified pneumo...         2020   \n",
       "4                                                NaN         2020   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...   \n",
       "1  Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...   \n",
       "2  Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...   \n",
       "3                   Deng, Sheng-Qun; Peng, Hong-Juan   \n",
       "4                                         Zhang, Wei   \n",
       "\n",
       "                        journal  Microsoft Academic Paper ID WHO #Covidence  \\\n",
       "0            Intensive Care Med                 2.002765e+09          #3252   \n",
       "1                Cell Discovery                 3.003431e+09          #1861   \n",
       "2  Journal of Clinical Medicine                 3.006065e+09          #1043   \n",
       "3                    J Clin Med                 1.776631e+08          #1999   \n",
       "4            Intensive Care Med                 3.006643e+09          #3242   \n",
       "\n",
       "  has_full_text  \n",
       "0          True  \n",
       "1          True  \n",
       "2          True  \n",
       "3          True  \n",
       "4         False  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#metaDataPath = \"/kaggle/input/CORD-19-research-challenge/2020-03-13/all_sources_metadata_2020-03-13.csv\"\n",
    "metaDataPath = \"~/Downloads/2020-03-13/all_sources_metadata_2020-03-13.csv\"\n",
    "metaData = pd.read_csv(metaDataPath, header = 0)\n",
    "print(\"The number of articles: \" + str(metaData.shape[0]))\n",
    "metaData.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Normalize abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time spent: 2.068min.\n"
     ]
    }
   ],
   "source": [
    "startTime = time.time()\n",
    "metaData[\"clean_abstract\"] = float(\"NaN\")\n",
    "metaData.loc[metaData[\"abstract\"].notnull(), \"clean_abstract\"] = \\\n",
    "metaData[\"abstract\"][metaData[\"abstract\"].notnull()].apply(lambda x: textNormalize(x))\n",
    "print(\"Time spent: \" + str(round((time.time() - startTime) / 60, 3)) + \"min.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Output the new metadata table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "metaData.to_csv(\"~/Downloads/2020-03-13/all_sources_metadata_2020-03-13_clean.csv\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Learn tf-idf vectorizer"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This section only needs to be run once. A tf-idf vectorizer will be learned from the normalized abstracts and saved to tf-idf_vectorizer.pkl in the output folder."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Read-in metadata with normalized abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>authors</th>\n",
       "      <th>journal</th>\n",
       "      <th>Microsoft Academic Paper ID</th>\n",
       "      <th>WHO #Covidence</th>\n",
       "      <th>has_full_text</th>\n",
       "      <th>clean_abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>c630ebcdf30652f0422c3ec12a00b50241dc9bd9</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Angiotensin-converting enzyme 2 (ACE2) as a SA...</td>\n",
       "      <td>10.1007/s00134-020-05985-9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125455.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>2.002765e+09</td>\n",
       "      <td>#3252</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>53eccda7977a31e3d0f565c884da036b1e85438e</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Comparative genetic analysis of the novel coro...</td>\n",
       "      <td>10.1038/s41421-020-0147-1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...</td>\n",
       "      <td>Cell Discovery</td>\n",
       "      <td>3.003431e+09</td>\n",
       "      <td>#1861</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>210a892deb1c61577f6fba58505fd65356ce6636</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Incubation Period and Other Epidemiological Ch...</td>\n",
       "      <td>10.3390/jcm9020538</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The geographic spread of 2019 novel coronaviru...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...</td>\n",
       "      <td>Journal of Clinical Medicine</td>\n",
       "      <td>3.006065e+09</td>\n",
       "      <td>#1043</td>\n",
       "      <td>True</td>\n",
       "      <td>geograph spread novel coronavirus covid infect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>e3b40cc8e0e137c416b4a2273a4dca94ae8178cc</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Characteristics of and Public Health Responses...</td>\n",
       "      <td>10.3390/jcm9020575</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32093211.0</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>In December 2019, cases of unidentified pneumo...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Deng, Sheng-Qun; Peng, Hong-Juan</td>\n",
       "      <td>J Clin Med</td>\n",
       "      <td>1.776631e+08</td>\n",
       "      <td>#1999</td>\n",
       "      <td>True</td>\n",
       "      <td>decemb case unidentifi pneumonia histori expos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>92c2c9839304b4f2bc1276d41b1aa885d8b364fd</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Imaging changes in severe COVID-19 pneumonia</td>\n",
       "      <td>10.1007/s00134-020-05976-w</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125453.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Wei</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>3.006643e+09</td>\n",
       "      <td>#3242</td>\n",
       "      <td>False</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0                                       sha source_x  \\\n",
       "0           0  c630ebcdf30652f0422c3ec12a00b50241dc9bd9      CZI   \n",
       "1           1  53eccda7977a31e3d0f565c884da036b1e85438e      CZI   \n",
       "2           2  210a892deb1c61577f6fba58505fd65356ce6636      CZI   \n",
       "3           3  e3b40cc8e0e137c416b4a2273a4dca94ae8178cc      CZI   \n",
       "4           4  92c2c9839304b4f2bc1276d41b1aa885d8b364fd      CZI   \n",
       "\n",
       "                                               title  \\\n",
       "0  Angiotensin-converting enzyme 2 (ACE2) as a SA...   \n",
       "1  Comparative genetic analysis of the novel coro...   \n",
       "2  Incubation Period and Other Epidemiological Ch...   \n",
       "3  Characteristics of and Public Health Responses...   \n",
       "4       Imaging changes in severe COVID-19 pneumonia   \n",
       "\n",
       "                          doi pmcid   pubmed_id   license  \\\n",
       "0  10.1007/s00134-020-05985-9   NaN  32125455.0  cc-by-nc   \n",
       "1   10.1038/s41421-020-0147-1   NaN         NaN     cc-by   \n",
       "2          10.3390/jcm9020538   NaN         NaN     cc-by   \n",
       "3          10.3390/jcm9020575   NaN  32093211.0     cc-by   \n",
       "4  10.1007/s00134-020-05976-w   NaN  32125453.0  cc-by-nc   \n",
       "\n",
       "                                            abstract publish_time  \\\n",
       "0                                                NaN         2020   \n",
       "1                                                NaN         2020   \n",
       "2  The geographic spread of 2019 novel coronaviru...         2020   \n",
       "3  In December 2019, cases of unidentified pneumo...         2020   \n",
       "4                                                NaN         2020   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...   \n",
       "1  Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...   \n",
       "2  Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...   \n",
       "3                   Deng, Sheng-Qun; Peng, Hong-Juan   \n",
       "4                                         Zhang, Wei   \n",
       "\n",
       "                        journal  Microsoft Academic Paper ID WHO #Covidence  \\\n",
       "0            Intensive Care Med                 2.002765e+09          #3252   \n",
       "1                Cell Discovery                 3.003431e+09          #1861   \n",
       "2  Journal of Clinical Medicine                 3.006065e+09          #1043   \n",
       "3                    J Clin Med                 1.776631e+08          #1999   \n",
       "4            Intensive Care Med                 3.006643e+09          #3242   \n",
       "\n",
       "  has_full_text                                     clean_abstract  \n",
       "0          True                                                NaN  \n",
       "1          True                                                NaN  \n",
       "2          True  geograph spread novel coronavirus covid infect...  \n",
       "3          True  decemb case unidentifi pneumonia histori expos...  \n",
       "4         False                                                NaN  "
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metaDataPath = \"~/Downloads/2020-03-13/all_sources_metadata_2020-03-13_clean.csv\"\n",
    "metaData = pd.read_csv(metaDataPath, header = 0)\n",
    "metaData.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Learn vocabulary and idf from the normalized abstracts\n",
    "To further constrain the searching space to focus more on coronavirus knowledge, we only include an article if either \"coron\" (for coronavirus) or \"covid\" are mentioned in its abstract. In this way, other articles that are more generally related to epidemic or other respiration diseases will be excluded. This filtering step also largely boosts learning and retrieval time. More strict rules can also be used to only include articles that are specifically related to COVID-19."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of remaining articles:  5246\n"
     ]
    }
   ],
   "source": [
    "metaData = metaData[metaData[\"clean_abstract\"].notnull()]\n",
    "metaData = metaData[metaData[\"clean_abstract\"].str.contains(\"|\".join([\"coron\", \"covid\"]))]\n",
    "print(\"The number of remaining articles: \", metaData.shape[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time spent: 3.8996529579162598s.\n"
     ]
    }
   ],
   "source": [
    "startTime = time.time()\n",
    "vectorizer = TfidfVectorizer(tokenizer = word_tokenize)\n",
    "vectorizer.fit(metaData[\"clean_abstract\"][metaData[\"clean_abstract\"].notnull()])\n",
    "print('Time spent: ' + str(time.time() - startTime) + 's.')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Save the learned vectorizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [],
   "source": [
    "vectPath = \"../../../Downloads/2020-03-13/tf-idf_vectorizer.pkl\"\n",
    "with open(vectPath, \"wb\") as vectFile:\n",
    "    pickle.dump(vectorizer, vectFile)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Retrieve relevant articles and sentences for each task"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Read-in metadata with normalized abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>authors</th>\n",
       "      <th>journal</th>\n",
       "      <th>Microsoft Academic Paper ID</th>\n",
       "      <th>WHO #Covidence</th>\n",
       "      <th>has_full_text</th>\n",
       "      <th>clean_abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>c630ebcdf30652f0422c3ec12a00b50241dc9bd9</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Angiotensin-converting enzyme 2 (ACE2) as a SA...</td>\n",
       "      <td>10.1007/s00134-020-05985-9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125455.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>2.002765e+09</td>\n",
       "      <td>#3252</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>53eccda7977a31e3d0f565c884da036b1e85438e</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Comparative genetic analysis of the novel coro...</td>\n",
       "      <td>10.1038/s41421-020-0147-1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...</td>\n",
       "      <td>Cell Discovery</td>\n",
       "      <td>3.003431e+09</td>\n",
       "      <td>#1861</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>210a892deb1c61577f6fba58505fd65356ce6636</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Incubation Period and Other Epidemiological Ch...</td>\n",
       "      <td>10.3390/jcm9020538</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The geographic spread of 2019 novel coronaviru...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...</td>\n",
       "      <td>Journal of Clinical Medicine</td>\n",
       "      <td>3.006065e+09</td>\n",
       "      <td>#1043</td>\n",
       "      <td>True</td>\n",
       "      <td>geograph spread novel coronavirus covid infect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>e3b40cc8e0e137c416b4a2273a4dca94ae8178cc</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Characteristics of and Public Health Responses...</td>\n",
       "      <td>10.3390/jcm9020575</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32093211.0</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>In December 2019, cases of unidentified pneumo...</td>\n",
       "      <td>2020</td>\n",
       "      <td>Deng, Sheng-Qun; Peng, Hong-Juan</td>\n",
       "      <td>J Clin Med</td>\n",
       "      <td>1.776631e+08</td>\n",
       "      <td>#1999</td>\n",
       "      <td>True</td>\n",
       "      <td>decemb case unidentifi pneumonia histori expos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>92c2c9839304b4f2bc1276d41b1aa885d8b364fd</td>\n",
       "      <td>CZI</td>\n",
       "      <td>Imaging changes in severe COVID-19 pneumonia</td>\n",
       "      <td>10.1007/s00134-020-05976-w</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32125453.0</td>\n",
       "      <td>cc-by-nc</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020</td>\n",
       "      <td>Zhang, Wei</td>\n",
       "      <td>Intensive Care Med</td>\n",
       "      <td>3.006643e+09</td>\n",
       "      <td>#3242</td>\n",
       "      <td>False</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0                                       sha source_x  \\\n",
       "0           0  c630ebcdf30652f0422c3ec12a00b50241dc9bd9      CZI   \n",
       "1           1  53eccda7977a31e3d0f565c884da036b1e85438e      CZI   \n",
       "2           2  210a892deb1c61577f6fba58505fd65356ce6636      CZI   \n",
       "3           3  e3b40cc8e0e137c416b4a2273a4dca94ae8178cc      CZI   \n",
       "4           4  92c2c9839304b4f2bc1276d41b1aa885d8b364fd      CZI   \n",
       "\n",
       "                                               title  \\\n",
       "0  Angiotensin-converting enzyme 2 (ACE2) as a SA...   \n",
       "1  Comparative genetic analysis of the novel coro...   \n",
       "2  Incubation Period and Other Epidemiological Ch...   \n",
       "3  Characteristics of and Public Health Responses...   \n",
       "4       Imaging changes in severe COVID-19 pneumonia   \n",
       "\n",
       "                          doi pmcid   pubmed_id   license  \\\n",
       "0  10.1007/s00134-020-05985-9   NaN  32125455.0  cc-by-nc   \n",
       "1   10.1038/s41421-020-0147-1   NaN         NaN     cc-by   \n",
       "2          10.3390/jcm9020538   NaN         NaN     cc-by   \n",
       "3          10.3390/jcm9020575   NaN  32093211.0     cc-by   \n",
       "4  10.1007/s00134-020-05976-w   NaN  32125453.0  cc-by-nc   \n",
       "\n",
       "                                            abstract publish_time  \\\n",
       "0                                                NaN         2020   \n",
       "1                                                NaN         2020   \n",
       "2  The geographic spread of 2019 novel coronaviru...         2020   \n",
       "3  In December 2019, cases of unidentified pneumo...         2020   \n",
       "4                                                NaN         2020   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Zhang, Haibo; Penninger, Josef M.; Li, Yimin; ...   \n",
       "1  Cao, Yanan; Li, Lin; Feng, Zhimin; Wan, Shengq...   \n",
       "2  Linton, M. Natalie; Kobayashi, Tetsuro; Yang, ...   \n",
       "3                   Deng, Sheng-Qun; Peng, Hong-Juan   \n",
       "4                                         Zhang, Wei   \n",
       "\n",
       "                        journal  Microsoft Academic Paper ID WHO #Covidence  \\\n",
       "0            Intensive Care Med                 2.002765e+09          #3252   \n",
       "1                Cell Discovery                 3.003431e+09          #1861   \n",
       "2  Journal of Clinical Medicine                 3.006065e+09          #1043   \n",
       "3                    J Clin Med                 1.776631e+08          #1999   \n",
       "4            Intensive Care Med                 3.006643e+09          #3242   \n",
       "\n",
       "  has_full_text                                     clean_abstract  \n",
       "0          True                                                NaN  \n",
       "1          True                                                NaN  \n",
       "2          True  geograph spread novel coronavirus covid infect...  \n",
       "3          True  decemb case unidentifi pneumonia histori expos...  \n",
       "4         False                                                NaN  "
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metaDataPath = \"~/Downloads/2020-03-13/all_sources_metadata_2020-03-13_clean.csv\"\n",
    "metaData = pd.read_csv(metaDataPath, header = 0)\n",
    "metaData.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "metaData = metaData[metaData[\"clean_abstract\"].notnull()]\n",
    "metaData = metaData[metaData[\"clean_abstract\"].str.contains(\"|\".join([\"coron\", \"covid\"]))]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load the tf-idf vectorizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "vectPath = \"../../../Downloads/2020-03-13/tf-idf_vectorizer.pkl\"\n",
    "with open(vectPath, 'rb') as vectFile:\n",
    "    vectorizer = pickle.load(vectFile)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Transfer abstracts to document-term matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "docTermMatrix = vectorizer.transform(metaData[\"clean_abstract\"][metaData[\"clean_abstract\"].notnull()]).toarray()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Queries for tasks\n",
    "We allow multiple queries for each task. The top relevant articles and sentences will be retrieved for each query. Below we give the example queries we used for each task. One may choose to run any one of them as the target queries or write new queries (in the form of a list of strings). Here we show the results of running the queries for task 1. At the end of the notebook, we provide a mixed short-cut for the results we got for all tasks."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 1: What is known about transmission, incubation, and environmental stability?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Range of incubation periods for the disease in humans (and how this varies across age and health status) and how long individuals are contagious, even after recovery.\",\n",
    "    \"Prevalence of asymptomatic shedding and transmission (e.g., particularly children).\",\n",
    "    \"Seasonality of transmission.\",\n",
    "    \"Physical science of the coronavirus (e.g., charge distribution, adhesion to hydrophilic/phobic surfaces, environmental survival to inform decontamination efforts for affected areas and provide information about viral shedding).\",\n",
    "    \"Persistence and stability on a multitude of substrates and sources (e.g., nasal discharge, sputum, urine, fecal matter, blood).\",\n",
    "    \"Persistence of virus on surfaces of different materials (e,g., copper, stainless steel, plastic).\",\n",
    "    \"Natural history of the virus and shedding of it from an infected person\",\n",
    "    \"Implementation of diagnostics and products to improve clinical processes\",\n",
    "    \"Disease models, including animal models for infection, disease and transmission\",\n",
    "    \"Tools and studies to monitor phenotypic change and potential adaptation of the virus\",\n",
    "    \"Immune response and immunity\",\n",
    "    \"Effectiveness of movement control strategies to prevent secondary transmission in health care and community settings\",\n",
    "    \"Effectiveness of personal protective equipment (PPE) and its usefulness to reduce risk of transmission in health care and community settings\",\n",
    "    \"Role of the environment in transmission\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 2: What do we know about COVID-19 risk factors?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Smoking, pre-existing pulmonary disease\",\n",
    "    \"Co-infections (determine whether co-existing respiratory/viral infections make the virus more transmissible or virulent) and other co-morbidities\",\n",
    "    \"Neonates and pregnant women\",\n",
    "    \"Socio-economic and behavioral factors to understand the economic impact of the virus and whether there were differences.\",\n",
    "    \"Transmission dynamics of the virus, including the basic reproductive number, incubation period, serial interval, modes of transmission and environmental factors\",\n",
    "    \"Severity of disease, including risk of fatality among symptomatic hospitalized patients, and high-risk patient groups\",\n",
    "    \"Susceptibility of populations\",\n",
    "    \"Public health mitigation measures that could be effective for control\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 3: What do we know about virus genetics, origin, and evolution?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Real-time tracking of whole genomes and a mechanism for coordinating the rapid dissemination of that information to inform the development of diagnostics and therapeutics and to track variations of the virus over time.\",\n",
    "    \"Access to geographic and temporal diverse sample sets to understand geographic distribution and genomic differences, and determine whether there is more than one strain in circulation. Multi-lateral agreements such as the Nagoya Protocol could be leveraged.\",\n",
    "    \"Evidence that livestock could be infected (e.g., field surveillance, genetic sequencing, receptor binding) and serve as a reservoir after the epidemic appears to be over.\",\n",
    "    \"Evidence of whether farmers are infected, and whether farmers could have played a role in the origin.\",\n",
    "    \"Surveillance of mixed wildlife- livestock farms for SARS-CoV-2 and other coronaviruses in Southeast Asia.\",\n",
    "    \"Experimental infections to test host range for this pathogen.\",\n",
    "    \"Animal host(s) and any evidence of continued spill-over to humans\",\n",
    "    \"Socioeconomic and behavioral risk factors for this spill-over\",\n",
    "    \"Sustainable risk reduction strategies\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 4: What do we know about vaccines and therapeutics?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Effectiveness of drugs being developed and tried to treat COVID-19 patients.\",\n",
    "    \"Clinical and bench trials to investigate less common viral inhibitors against COVID-19 such as naproxen, clarithromycin, and minocyclinethat that may exert effects on viral replication.\",\n",
    "    \"Methods evaluating potential complication of Antibody-Dependent Enhancement (ADE) in vaccine recipients.\",\n",
    "    \"Exploration of use of best animal models and their predictive value for a human vaccine.\",\n",
    "    \"Capabilities to discover a therapeutic (not vaccine) for the disease, and clinical effectiveness studies to discover therapeutics, to include antiviral agents.\",\n",
    "    \"Alternative models to aid decision makers in determining how to prioritize and distribute scarce, newly proven therapeutics as production ramps up. This could include identifying approaches for expanding production capacity to ensure equitable and timely distribution to populations in need.\",\n",
    "    \"Efforts targeted at a universal coronavirus vaccine.\",\n",
    "    \"Efforts to develop animal models and standardize challenge studies\",\n",
    "    \"Efforts to develop prophylaxis clinical studies and prioritize in healthcare workers\",\n",
    "    \"Approaches to evaluate risk for enhanced disease after vaccination\",\n",
    "    \"Assays to evaluate vaccine immune response and process development for vaccines, alongside suitable animal models in conjunction with therapeutics\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 5: What has been published about medical care?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Resources to support skilled nursing facilities and long term care facilities.\",\n",
    "    \"Mobilization of surge medical staff to address shortages in overwhelmed communities\",\n",
    "    \"Age-adjusted mortality data for Acute Respiratory Distress Syndrome (ARDS) with/without other organ failure  particularly for viral etiologies\",\n",
    "    \"Extracorporeal membrane oxygenation (ECMO) outcomes data of COVID-19 patients\",\n",
    "    \"Outcomes data for COVID-19 after mechanical ventilation adjusted for age.\",\n",
    "    \"Knowledge of the frequency, manifestations, and course of extrapulmonary manifestations of COVID-19, including, but not limited to, possible cardiomyopathy and cardiac arrest.\",\n",
    "    \"Application of regulatory standards (e.g., EUA, CLIA) and ability to adapt care to crisis standards of care level.\",\n",
    "    \"Approaches for encouraging and facilitating the production of elastomeric respirators, which can save thousands of N95 masks.\",\n",
    "    \"Best telemedicine practices, barriers and faciitators, and specific actions to remove/expand them within and across state boundaries.\",\n",
    "    \"Guidance on the simple things people can do at home to take care of sick people and manage disease.\",\n",
    "    \"Oral medications that might potentially work.\",\n",
    "    \"Use of AI in real-time health care delivery to evaluate interventions, risk factors, and outcomes in a way that could not be done manually.\",\n",
    "    \"Best practices and critical challenges and innovative solutions and technologies in hospital flow and organization, workforce protection, workforce allocation, community-based support resources, payment, and supply chain management to enhance capacity, efficiency, and outcomes.\",\n",
    "    \"Efforts to define the natural history of disease to inform clinical care, public health interventions, infection prevention control, transmission, and clinical trials\",\n",
    "    \"Efforts to develop a core clinical outcome set to maximize usability of data across a range of trials\",\n",
    "    \"Efforts to determine adjunctive and supportive interventions that can improve the clinical outcomes of infected patients (e.g. steroids, high flow oxygen)\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 6: What do we know about non-pharmaceutical interventions?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Guidance on ways to scale up NPIs in a more coordinated way (e.g., establish funding, infrastructure and authorities to support real time, authoritative (qualified participants) collaboration with all states to gain consensus on consistent guidance and to mobilize resources to geographic areas where critical shortfalls are identified) to give us time to enhance our health care delivery system capacity to respond to an increase in cases.\",\n",
    "    \"Rapid design and execution of experiments to examine and compare NPIs currently being implemented. DHS Centers for Excellence could potentially be leveraged to conduct these experiments.\",\n",
    "    \"Rapid assessment of the likely efficacy of school closures, travel bans, bans on mass gatherings of various sizes, and other social distancing approaches.\",\n",
    "    \"Methods to control the spread in communities, barriers to compliance and how these vary among different populations.\",\n",
    "    \"Models of potential interventions to predict costs and benefits that take account of such factors as race, income, disability, age, geographic location, immigration status, housing status, employment status, and health insurance status.\",\n",
    "    \"Policy changes necessary to enable the compliance of individuals with limited resources and the underserved with NPIs.\",\n",
    "    \"Research on why people fail to comply with public health advice, even if they want to do so (e.g., social or financial costs may be too high).\",\n",
    "    \"Research on the economic impact of this or any pandemic. This would include identifying policy and programmatic alternatives that lessen/mitigate risks to critical government services, food distribution and supplies, access to critical household supplies, and access to health diagnoses, treatment, and needed care, regardless of ability to pay.\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 7: Sample task with sample submission"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Are there geographic variations in the rate of COVID-19 spread?\",\n",
    "    \"Are there geographic variations in the mortality rate of COVID-19?\",\n",
    "    \"there any evidence to suggest geographic based virus mutations?\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 8: What do we know about diagnostics and surveillance?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"How widespread current exposure is to be able to make immediate policy recommendations on mitigation measures. Denominators for testing and a mechanism for rapidly sharing that information, including demographics, to the extent possible. Sampling methods to determine asymptomatic disease (e.g., use of serosurveys (such as convalescent samples) and early detection of disease (e.g., use of screening of neutralizing antibodies such as ELISAs).\",\n",
    "    \"Efforts to increase capacity on existing diagnostic platforms and tap into existing surveillance platforms.\",\n",
    "    \"Recruitment, support, and coordination of local expertise and capacity (public, privatecommercial, and non-profit, including academic), including legal, ethical, communications, and operational issues.\",\n",
    "    \"National guidance and guidelines about best practices to states (e.g., how states might leverage universities and private laboratories for testing purposes, communications to public health officials and the public).\",\n",
    "    \"Development of a point-of-care test (like a rapid influenza test) and rapid bed-side tests, recognizing the tradeoffs between speed, accessibility, and accuracy.\",\n",
    "    \"Rapid design and execution of targeted surveillance experiments calling for all potential testers using PCR in a defined area to start testing and report to a specific entity. These experiments could aid in collecting longitudinal samples, which are critical to understanding the impact of ad hoc local interventions (which also need to be recorded).\",\n",
    "    \"Separation of assay development issues from instruments, and the role of the private sector to help quickly migrate assays onto those devices.\",\n",
    "    \"Efforts to track the evolution of the virus (i.e., genetic drift or mutations) and avoid locking into specific reagents and surveillance/detection schemes.\",\n",
    "    \"Latency issues and when there is sufficient viral load to detect the pathogen, and understanding of what is needed in terms of biological and environmental sampling.\",\n",
    "    \"Use of diagnostics such as host response markers (e.g., cytokines) to detect early disease or predict severe disease progression, which would be important to understanding best clinical practice and efficacy of therapeutic interventions.\",\n",
    "    \"Policies and protocols for screening and testing.\",\n",
    "    \"Policies to mitigate the effects on supplies associated with mass testing, including swabs and reagents.\",\n",
    "    \"Technology roadmap for diagnostics.\",\n",
    "    \"Barriers to developing and scaling up new diagnostic tests (e.g., market forces), how future coalition and accelerator models (e.g., Coalition for Epidemic Preparedness Innovations) could provide critical funding for diagnostics, and opportunities for a streamlined regulatory environment.\",\n",
    "    \"New platforms and technology (e.g., CRISPR) to improve response times and employ more holistic approaches to COVID-19 and future diseases.\",\n",
    "    \"Coupling genomics and diagnostic testing on a large scale.\",\n",
    "    \"Enhance capabilities for rapid sequencing and bioinformatics to target regions of the genome that will allow specificity for a particular variant.\",\n",
    "    \"Enhance capacity (people, technology, data) for sequencing with advanced analytics for unknown pathogens, and explore capabilities for distinguishing naturally-occurring pathogens from intentional.\",\n",
    "    \"One Health surveillance of humans and potential sources of future spillover or ongoing exposure for this organism and future pathogens, including both evolutionary hosts (e.g., bats) and transmission hosts (e.g., heavily trafficked and farmed wildlife and domestic food and companion species), inclusive of environmental, demographic, and occupational risk factors.\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 9: What has been published about ethical and social science considerations?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Efforts to articulate and translate existing ethical principles and standards to salient issues in COVID-2019\",\n",
    "    \"Efforts to embed ethics across all thematic areas, engage with novel ethical issues that arise and coordinate to minimize duplication of oversight\",\n",
    "    \"Efforts to support sustained education, access, and capacity building in the area of ethics\",\n",
    "    \"Efforts to establish a team at WHO that will be integrated within multidisciplinary research and operational platforms and that will connect with existing and expanded global networks of social sciences.\",\n",
    "    \"Efforts to develop qualitative assessment frameworks to systematically collect information related to local barriers and enablers for the uptake and adherence to public health measures for prevention and control. This includes the rapid identification of the secondary impacts of these measures. (e.g. use of surgical masks, modification of health seeking behaviors for SRH, school closures)\",\n",
    "    \"Efforts to identify how the burden of responding to the outbreak and implementing public health measures affects the physical and psychological health of those providing care for Covid-19 patients and identify the immediate needs that must be addressed.\",\n",
    "    \"Efforts to identify the underlying drivers of fear, anxiety and stigma that fuel misinformation and rumor, particularly through social media.\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 10: What has been published about information sharing and inter-sectoral collaboration?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [],
   "source": [
    "queries = [\n",
    "    \"Methods for coordinating data-gathering with standardized nomenclature.\",\n",
    "    \"Sharing response information among planners, providers, and others.\",\n",
    "    \"Understanding and mitigating barriers to information-sharing.\",\n",
    "    \"How to recruit, support, and coordinate local (non-Federal) expertise and capacity relevant to public health emergency response (public, private, commercial and non-profit, including academic).\",\n",
    "    \"Integration of federal/state/local public health surveillance systems.\",\n",
    "    \"Value of investments in baseline public health response infrastructure preparedness\",\n",
    "    \"Modes of communicating with target high-risk populations (elderly, health care workers).\",\n",
    "    \"Risk communication and guidelines that are easy to understand and follow (include targeting at risk populations families too).\",\n",
    "    \"Communication that indicates potential risk of disease to all population groups.\",\n",
    "    \"Misunderstanding around containment and mitigation.\",\n",
    "    \"Action plan to mitigate gaps and problems of inequity in the Nations public health capability, capacity, and funding to ensure all citizens in need are supported and can access information, surveillance, and treatment.\",\n",
    "    \"Measures to reach marginalized and disadvantaged populations.Data systems and research priorities and agendas incorporate attention to the needs and circumstances of disadvantaged populations and underrepresented minorities.\",\n",
    "    \"Mitigating threats to incarcerated people from COVID-19, assuring access to information, prevention, diagnosis, and treatment.\",\n",
    "    \"Understanding coverage policies (barriers and opportunities) related to testing, treatment, and care\"\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Transfer queries to query-term matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "normQueries = [textNormalize(q) for q in queries] # Text normalization for all queries\n",
    "queryTermMatrix = vectorizer.transform(normQueries).toarray()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Level 1: retrieve top related articles based on cosine similarity between tf-idf vectors"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Compute cosine similarity between each query and all abstracts."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time spent: 1.27s.\n"
     ]
    }
   ],
   "source": [
    "startTime = time.time()\n",
    "queryDocDist = 1 - cdist(queryTermMatrix, docTermMatrix, metric = 'cosine')\n",
    "print(\"Time spent: \" + str(round((time.time() - startTime), 3)) + \"s.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieveTopLiter(queries, queryDocDist, outputPath, nDoc = 5, showResults = True):\n",
    "    \"\"\"\n",
    "    Function to retrieve the top n literatures for each query based on cosine similarities between query tf-idf \n",
    "    representations and literature tf-idf representations. \n",
    "    Input:\n",
    "        queries: a list of m strings where each string is a text normalized query.\n",
    "        queryDocDist: a m x n array that gives the pairwise cosine similarity between the m queries and n literatures.\n",
    "        outputPath: a string specifies the path to the output file.\n",
    "        nDoc (default 5): the number of literatures to be retrieved for each query.\n",
    "        showResults (default True): whether show the results in the terminal.\n",
    "    Output:\n",
    "        The abstract and metadata of the retrieved literatures will be written to the output file specified by\n",
    "        outputPath.\n",
    "    \"\"\"\n",
    "    outputFile = open(outputPath, \"w\")\n",
    "    for i in range(len(queries)):\n",
    "        print(\"Query: \", queries[i])\n",
    "        print(\"\")\n",
    "        outputFile.write(\"Query: \" + queries[i] + \"\\n\\n\")\n",
    "        docCount = 1\n",
    "        for idx in queryDocDist[i].argsort()[-nDoc:][::-1]:\n",
    "            docMeta = metaData[metaData[\"abstract\"].notnull()].iloc[idx]\n",
    "            if showResults:\n",
    "                print(\"#\" + str(docCount) + \" article\")\n",
    "                print(\"Cosine similarity: \", queryDocDist[i][idx])\n",
    "                print(\"PMC_ID: \", docMeta[\"pmcid\"])\n",
    "                print(\"Title: \", docMeta[\"title\"])\n",
    "                print(\"Abstract: \", docMeta[\"abstract\"])\n",
    "                print(\"Has full text: \", docMeta[\"has_full_text\"])\n",
    "                print(\"\")\n",
    "            \n",
    "            outputFile.write(\"#\" + str(docCount) + \" article\\n\")\n",
    "            outputFile.write(\"Cosine similarity: \" + str(round(queryDocDist[i][idx], 5)) + \"\\n\")\n",
    "            outputFile.write(\"PMC_ID: \" + str(docMeta[\"pmcid\"]) + \"\\n\")\n",
    "            outputFile.write(\"Title: \" + docMeta[\"title\"] + \"\\n\")\n",
    "            outputFile.write(\"Abstract: \" + docMeta[\"abstract\"] + \"\\n\")\n",
    "            outputFile.write(\"Has full text: \" + str(docMeta[\"has_full_text\"]) + \"\\n\\n\")\n",
    "            \n",
    "            docCount += 1\n",
    "    outputFile.close()\n",
    "    return"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "List out the meta information for top 5 related articles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query:  Effectiveness of drugs being developed and tried to treat COVID-19 patients.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.29476092869037784\n",
      "PMC_ID:  nan\n",
      "Title:  Management and clinical thinking of Coronavirus Disease 2019\n",
      "Abstract:  In December 2019, the 2019 novel coronavirus pneumonia (NCP, officially named Coronavirus Disease 2019(COVID-19) by the World Health Organization) broke out in Wuhan, Hubei, and it quickly spread to the whole country and abroad. The situation was at stake. The sudden and serious COVID-19 epidemic has brought us a lot of urgent problems. How to effectively control the spread of COVID-19? When does the population infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to effectively treat with existing drugs? Can it successfully improve the survival rate of critically patients? In response to the above questions, we put forward corresponding suggestions and reflections from the perspective of the infectious clinician.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.2832366679581708\n",
      "PMC_ID:  nan\n",
      "Title:  CT Imaging and Differential Diagnosis of COVID-19\n",
      "Abstract:  Since the beginning of 2020, coronavirus disease 2019 (COVID-19) has spread throughout China. This study explains the findings from lung computed tomography images of some patients with COVID-19 treated in this medical institution and discusses the difference between COVID-19 and other lung diseases.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.2788932567187199\n",
      "PMC_ID:  nan\n",
      "Title:  Drug trials under way\n",
      "Abstract:  We'll soon know if covid-19 can be treated with drugs developed for HIV and Ebola, reports Alice Klein\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.2755896903086825\n",
      "PMC_ID:  nan\n",
      "Title:  Strategies suggested for emergency diagnosis and treatment of traumatic orthopedicsin the epidemic periodof Corona Virus Disease 2019\n",
      "Abstract:  Objective To suggest strategies for emergency diagnosis and treatment of trauma orthopedics in the epidemic period of Corona Virus Disease 2019(COVID-19). Methods In the epidemic of COVID-19 from January 21 to February 15, 2020, 128 patients with orthopaedic trauma sought emergency treatment at Department of Orthopedic Surgery, The People&rsquo;s Hospital of Wuhan University. They were 71 males and 57 females with an average age of 48.7 years (from 5 to 88 years).Of them, 107 cases were treated at the outpatient department and 21 hospitalized. Emergency operations were carried out for 4 cases and selective operationsfor 17 cases. COVID-19 infections were recorded in the patients and medical staff as well. Measures taken and experiences learned were summarized since the epidemicoutbreak of COVID-19. Results Of the 107 cases treated at the outpatient department, 3 had a definite diagnosis of COVID-19 and 3 a suspected diagnosis of COVID-19. Of the 4 cases undergoing emergency surgery, one was suspected of having COVID-19. Of the 17 cases undergoing selective surgery, one was diagnosed definitely as COVID-19and 2 were suspected of COVID-19. Two nurses were diagnosed definitely as having mildCOVID-19.One doctor and one nurse were suspected of COVID-19. Since the COVID-19 infections in medical staff occurred all before the preventive and control measures for COVID-19 had been implemented,is was not ruled out that their infections might have come from communities. Conclusions It is particularly important for medical institutions of all levels to maintain safe and effective routine services while doing well in COVID-19 prevention. In the epidemic of COVID-19, front-line medical staff in emergency traumatic orthopedics is faced with great challenges in the process of diagnosing and treating patients. High-quality and safe medical services can be provided as long as nosocomial COVID-19infection is effectively controlled by rigid screening of patientsnewly admitted, classified management of inpatients, optimal management of inpatient wards, standard preventive measures in perioperative period, a perfect system for medical protection, and medical education for patients and their carers.\n",
      "Has full text:  nan\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.25495704525130336\n",
      "PMC_ID:  nan\n",
      "Title:  COVID-19 (Novel Coronavirus 2019) - recent trends\n",
      "Abstract:  The World Health Organization (WHO) has issued a warning that, although the 2019 novel coronavirus (COVID-19) from Wuhan City (China), is not pandemic, it should be contained to prevent the global spread. The COVID-19 virus was known earlier as 2019-nCoV. As of 12 February 2020, WHO reported 45,171 cases and 1115 deaths related to COVID-19. COVID-19 is similar to Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) virus in its pathogenicity, clinical spectrum, and epidemiology. Comparison of the genome sequences of COVID-19, SARS-CoV, and Middle East Respiratory Syndrome coronavirus (MERS-CoV) showed that COVID-19 has a better sequence identity with SARS-CoV compared to MERS CoV. However, the amino acid sequence of COVID-19 differs from other coronaviruses specifically in the regions of 1ab polyprotein and surface glycoprotein or S-protein. Although several animals have been speculated to be a reservoir for COVID-19, no animal reservoir has been already confirmed. COVID-19 causes COVID-19 disease that has similar symptoms as SARS-CoV. Studies suggest that the human receptor for COVID-19 may be angiotensin-converting enzyme 2 (ACE2) receptor similar to that of SARS-CoV. The nucleocapsid (N) protein of COVID-19 has nearly 90% amino acid sequence identity with SARS-CoV. The N protein antibodies of SARS-CoV may cross react with COVID-19 but may not provide cross-immunity. In a similar fashion to SARS-CoV, the N protein of COVID-19 may play an important role in suppressing the RNA interference (RNAi) to overcome the host defense. This mini-review aims at investigating the most recent trend of COVID-19.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Clinical and bench trials to investigate less common viral inhibitors against COVID-19 such as naproxen, clarithromycin, and minocyclinethat that may exert effects on viral replication.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.25619930766828547\n",
      "PMC_ID:  nan\n",
      "Title:  Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need\n",
      "Abstract:  Clinical trial for COVID-19 was first registered on January 23, 2020. In the last few weeks, an escalating number of clinical trials has been planned and registered with ongoing investigations taking place. From the Chinese Clinical Trial Registry (http://www.chictr.org.cn) and U.S. National Library of Medicine Clinical Trial Registry (https://clinicaltrials. gov), there are 125 clinical trials registered by February 18, 2020, focusing on the treatment of COVID-19. There is an upward trend on the number of registered clinical trials (Figure 1). Among the 125 clinical trials on treatment, 33.3% used anti-viral agents, 14.7% anti-inflammation or immunomodulators, 33.3% herbs or traditional Chinese medicine (TCM), 9.3% cell-based therapy, 2.3% antioxidation and 7.0% other approaches. Pharmaceutical companies, government, institutions, physicians and scientists are the main force behind these researches. 17 years ago (2003), SARS affectedAU - Zhang, Tengyue\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.2258581157624001\n",
      "PMC_ID:  nan\n",
      "Title:  Key points of serious adverse eventand protection of patients in ophthalmic clinical trials during novel coronavirus pneumonia outbreak\n",
      "Abstract:  The prevention and control of novel coronavirus pneumonia is the most priority recently, and various measures during the prevention and control period will have varying degrees of impact on the implement of clinical trials. However, various examinations in ophthalmological clinical trials need close contact between operators and patients, which put us at risk of cross-infection. This paper indicated some suggestions based on the criteria of clinical trials under major public health emergencies, the management of clinical trials during epidemic period including the follow-up of subjects, the treatment of epidemic serious adverse event (SAE) and the management requirements of co-sponsors, as well as the requirements and management principles for environment, subjects, examiners and inspection equipment in the process of ophthalmic clinical trials. It may be helpful to the ophthalmic clinical trial researchers and subjects during the period of novel coronavirus infection.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.2018047619405281\n",
      "PMC_ID:  nan\n",
      "Title:  COVID-19 (Novel Coronavirus 2019) - recent trends\n",
      "Abstract:  The World Health Organization (WHO) has issued a warning that, although the 2019 novel coronavirus (COVID-19) from Wuhan City (China), is not pandemic, it should be contained to prevent the global spread. The COVID-19 virus was known earlier as 2019-nCoV. As of 12 February 2020, WHO reported 45,171 cases and 1115 deaths related to COVID-19. COVID-19 is similar to Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) virus in its pathogenicity, clinical spectrum, and epidemiology. Comparison of the genome sequences of COVID-19, SARS-CoV, and Middle East Respiratory Syndrome coronavirus (MERS-CoV) showed that COVID-19 has a better sequence identity with SARS-CoV compared to MERS CoV. However, the amino acid sequence of COVID-19 differs from other coronaviruses specifically in the regions of 1ab polyprotein and surface glycoprotein or S-protein. Although several animals have been speculated to be a reservoir for COVID-19, no animal reservoir has been already confirmed. COVID-19 causes COVID-19 disease that has similar symptoms as SARS-CoV. Studies suggest that the human receptor for COVID-19 may be angiotensin-converting enzyme 2 (ACE2) receptor similar to that of SARS-CoV. The nucleocapsid (N) protein of COVID-19 has nearly 90% amino acid sequence identity with SARS-CoV. The N protein antibodies of SARS-CoV may cross react with COVID-19 but may not provide cross-immunity. In a similar fashion to SARS-CoV, the N protein of COVID-19 may play an important role in suppressing the RNA interference (RNAi) to overcome the host defense. This mini-review aims at investigating the most recent trend of COVID-19.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.16467939991160851\n",
      "PMC_ID:  nan\n",
      "Title:  Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths\n",
      "Abstract:  Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2,000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.\n",
      "Has full text:  True\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.15775983735223842\n",
      "PMC_ID:  PMC4178758\n",
      "Title:  Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance\n",
      "Abstract:  Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease. Protease inhibitors blocking the replication of coronavirus (CoV), including the causative agents of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), provide a promising foundation for the development of anticoronaviral therapeutics. However, the selection and consequences of inhibitor-resistant CoVs are unknown. In this study, we exploited the model coronavirus, mouse hepatitis virus (MHV), to investigate the genotype and phenotype of MHV quasispecies selected for resistance to a broad-spectrum CoV 3C-like protease (3CLpro) inhibitor. Clonal sequencing identified single or double mutations within the 3CLpro coding sequence of inhibitor-resistant virus. Using reverse genetics to generate isogenic viruses with mutant 3CLpros, we found that viruses encoding double-mutant 3CLpros are fully resistant to the inhibitor and exhibit a significant delay in proteolytic processing of the viral replicase polyprotein. The inhibitor-resistant viruses also exhibited postponed and reduced production of infectious virus particles. Biochemical analysis verified double-mutant 3CLpro enzyme as impaired for protease activity and exhibiting reduced sensitivity to the inhibitor and revealed a delayed kinetics of inhibitor hydrolysis and activity restoration. Furthermore, the inhibitor-resistant virus was shown to be highly attenuated in mice. Our study provides the first insight into the pathogenicity and mechanism of 3CLpro inhibitor-resistant CoV mutants, revealing a low genetic barrier but high fitness cost of resistance. IMPORTANCE RNA viruses are infamous for their ability to evolve in response to selective pressure, such as the presence of antiviral drugs. For coronaviruses such as the causative agent of Middle East respiratory syndrome (MERS), protease inhibitors have been developed and shown to block virus replication, but the consequences of selection of inhibitor-resistant mutants have not been studied. Here, we report the low genetic barrier and relatively high deleterious consequences of CoV resistance to a 3CLpro protease inhibitor in a coronavirus model system, mouse hepatitis virus (MHV). We found that although mutations that confer resistance arise quickly, the resistant viruses replicate slowly and do not cause lethal disease in mice. Overall, our study provides the first analysis of the low barrier but high cost of resistance to a CoV 3CLpro inhibitor, which will facilitate the further development of protease inhibitors as anti-coronavirus therapeutics.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Methods evaluating potential complication of Antibody-Dependent Enhancement (ADE) in vaccine recipients.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.37911840938590036\n",
      "PMC_ID:  PMC1257724\n",
      "Title:  Dynamic effects of antibody-dependent enhancement on the fitness of viruses\n",
      "Abstract:  Antibody-dependent enhancement (ADE), a phenomenon in which viral replication is increased rather than decreased by immune sera, has been observed in vitro for a large number of viruses of public health importance, including flaviviruses, coronaviruses, and retroviruses. The most striking in vivo example of ADE in humans is dengue hemorrhagic fever, a disease in which ADE is thought to increase the severity of clinical manifestations of dengue virus infection by increasing virus replication. We examine the epidemiological impact of ADE on the prevalence and persistence of viral serotypes. Using a dynamical system model of n cocirculating dengue serotypes, we find that ADE may provide a competitive advantage to those serotypes that undergo enhancement compared with those that do not, and that this advantage increases with increasing numbers of cocirculating serotypes. Paradoxically, there are limits to the selective advantage provided by increasing levels of ADE, because greater levels of enhancement induce large amplitude oscillations in incidence of all dengue virus infections, threatening the persistence of both the enhanced and nonenhanced serotypes. Although the models presented here are specifically designed for dengue, our results are applicable to any epidemiological system in which partial immunity increases pathogen replication rates. Our results suggest that enhancement is most advantageous in settings where multiple serotypes circulate and where a large host population is available to support pathogen persistence during the deep troughs of ADE-induced large amplitude oscillations of virus replication.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.34526876822700925\n",
      "PMC_ID:  nan\n",
      "Title:  Is COVID-19 Receiving ADE From Other Coronaviruses?\n",
      "Abstract:  One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world. One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses. ADE modulates the immune response and can elicit sustained inflammation, lymphopenia, and/or cytokine storm, one or all of which have been documented in severe cases and deaths. ADE also requires prior exposure to similar antigenic epitopes, presumably circulating in local viruses, making it a possible explanation for the observed geographic limitation of severe cases and deaths.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.3377894263996136\n",
      "PMC_ID:  nan\n",
      "Title:  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry\n",
      "Abstract:  Antibody-dependent enhancement (ADE) of viral entry has been a major concern for epidemiology, vaccine development, and antibody-based drug therapy. However, the molecular mechanism behind ADE is still elusive. Coronavirus spike protein mediates viral entry into cells by first binding to a receptor on the host cell surface and then fusing viral and host membranes. In this study, we investigated how a neutralizing monoclonal antibody (MAb), which targets the receptor-binding domain (RBD) of Middle East respiratory syndrome (MERS) coronavirus spike, mediates viral entry using pseudovirus entry and biochemical assays. Our results showed that MAb binds to the virus surface spike, allowing it to undergo conformational changes and become prone to proteolytic activation. Meanwhile, MAb binds to cell surface IgG Fc receptor, guiding viral entry through canonical viral-receptor-dependent pathways. Our data suggest that the antibody/Fc-receptor complex functionally mimics viral receptor in mediating viral entry. Moreover, we characterized MAb dosages in viral-receptor-dependent, Fc-receptor-dependent, and both-receptors-dependent viral entry pathways, delineating guidelines on MAb usages in treating viral infections. Our study reveals a novel molecular mechanism for antibody-enhanced viral entry and can guide future vaccination and antiviral strategies.IMPORTANCE Antibody-dependent enhancement (ADE) of viral entry has been observed for many viruses. It was shown that antibodies target one serotype of viruses but only subneutralize another, leading to ADE of the latter viruses. Here we identify a novel mechanism for ADE: a neutralizing antibody binds to the surface spike protein of coronaviruses like a viral receptor, triggers a conformational change of the spike, and mediates viral entry into IgG Fc receptor-expressing cells through canonical viral-receptor-dependent pathways. We further evaluated how antibody dosages impacted viral entry into cells expressing viral receptor, Fc receptor, or both receptors. This study reveals complex roles of antibodies in viral entry and can guide future vaccine design and antibody-based drug therapy.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.3178433750847207\n",
      "PMC_ID:  PMC240165\n",
      "Title:  Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus.\n",
      "Abstract:  Fifty-four monoclonal antibodies (MAbs) to feline infectious peritonitis virus (FIPV) were characterized according to protein specificity, immunoglobulin subclass, virus neutralization, reactivity with different coronaviruses, and ability to induce antibody-dependent enhancement (ADE) of FIPV infection in vitro. The MAbs were found to be specific for one of three structural proteins of FIPV. A total of 47 MAbs were specific for the 205-kDa spike protein (S), 3 MAbs were specific for the 45-kDa nucleocapsid protein (N), and 4 MAbs were specific for the 26- to 28-kDa membrane protein (M). The S-specific MAbs showed various degrees of cross-reactivity with strains of FIPV, feline enteric coronavirus, canine coronavirus, and porcine transmissible gastroenteritis virus. Nineteen S-specific MAbs neutralized FIPV. A total of 15 of the neutralizing MAbs induced ADE, and all but 1 were of the immunoglobulin G2a subclass. The remaining four neutralizing MAbs that did not induce ADE were of the immunoglobulin G1 subclass. Two S-specific MAbs induced ADE but were nonneutralizing. None of the N- or M-specific MAbs was neutralizing or induced ADE. On the basis of the reactivity patterns of the MAbs with FIPV and related coronaviruses, it was concluded that there is a minimum of five neutralizing sites on S. In most instances, neutralizing MAbs were able to induce ADE, demonstrating a direct relationship between neutralization and enhancement. The difference in immunoglobulin subclass between neutralizing MAbs that induced ADE and those that did not induce ADE suggests that there may be a restriction in the immunoglobulin subclasses capable of mediating ADE.\n",
      "Has full text:  nan\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.2910271045321712\n",
      "PMC_ID:  PMC3187504\n",
      "Title:  Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcR Pathway\n",
      "Abstract:  Public health measures successfully contained outbreaks of the severe acute respiratory syndrome coronavirus (SARS-CoV) infection. However, the precursor of the SARS-CoV remains in its natural bat reservoir, and reemergence of a human-adapted SARS-like coronavirus remains a plausible public health concern. Vaccination is a major strategy for containing resurgence of SARS in humans, and a number of vaccine candidates have been tested in experimental animal models. We previously reported that antibody elicited by a SARS-CoV vaccine candidate based on recombinant full-length Spike-protein trimers potentiated infection of human B cell lines despite eliciting in vivo a neutralizing and protective immune response in rodents. These observations prompted us to investigate the mechanisms underlying antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro. We demonstrate here that anti-Spike immune serum, while inhibiting viral entry in a permissive cell line, potentiated infection of immune cells by SARS-CoV Spike-pseudotyped lentiviral particles, as well as replication-competent SARS coronavirus. Antibody-mediated infection was dependent on Fc receptor II but did not use the endosomal/lysosomal pathway utilized by angiotensin I converting enzyme 2 (ACE2), the accepted receptor for SARS-CoV. This suggests that ADE of SARS-CoV utilizes a novel cell entry mechanism into immune cells. Different SARS vaccine candidates elicit sera that differ in their capacity to induce ADE in immune cells despite their comparable potency to neutralize infection in ACE2-bearing cells. Our results suggest a novel mechanism by which SARS-CoV can enter target cells and illustrate the potential pitfalls associated with immunization against it. These findings should prompt further investigations into SARS pathogenesis.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Exploration of use of best animal models and their predictive value for a human vaccine.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.31942869073399704\n",
      "PMC_ID:  nan\n",
      "Title:  Reconsideration on the multiple value of Behavior determining Health: in the perspective of the situation of COVID-19\n",
      "Abstract:  Why has the concept of behavior determining health created more and more extensive and far-reaching influence ever since it was put forward? The reason lies in its multiple values. It is of great practical significance and has important implications for long-term health care to explore and analyze in the perspective of the situation of COVID-19 its philosophical values, cultural values, methodological values, social values and the national strategic value of 'healthy China'.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.25054567813612527\n",
      "PMC_ID:  PMC3644300\n",
      "Title:  Animal models for highly pathogenic emerging viruses\n",
      "Abstract:  Exotic and emerging viral pathogens associated with high morbidity and mortality in humans are being identified annually with recent examples including Lujo virus in southern Africa, Severe fever with Thrombocytopenia virus in China and a SARS-like coronavirus in the Middle East. The sporadic nature of these infections hampers our understanding of these diseases and limits the opportunities to design appropriate medical countermeasures against them. Due to this, animal models are utilized to gain insight into the pathogenesis of disease with the overall goal of identifying potential targets for intervention and evaluating specific therapeutics and vaccines. For these reasons it is imperative that animal models of disease recapitulate the human condition as closely as possible in order to provide the best predictive data with respect to the potential efficacy in humans. In this article we review the current status of disease models for highly pathogenic and emerging viral pathogens.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.23099781381510054\n",
      "PMC_ID:  PMC2633062\n",
      "Title:  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease\n",
      "Abstract:  An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines, such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.21881193698871215\n",
      "PMC_ID:  nan\n",
      "Title:  Application of the ARIMA model on the COVID-2019 epidemic dataset\n",
      "Abstract:  Coronavirus disease 2019 (COVID-2019) has been recognized as a global threat, and several studies are being conducted using various mathematical models to predict the probable evolution of this epidemic. These mathematical models based on various factors and analyses are subject to potential bias. Here, we propose a simple econometric model that could be useful to predict the spread of COVID-2019. We performed Auto Regressive Integrated Moving Average (ARIMA) model prediction on the Johns Hopkins epidemiological data to predict the epidemiological trend of the prevalence and incidence of COVID-2019. For further comparison or for future perspective, case definition and data collection have to be maintained in real time.\n",
      "Has full text:  True\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.20428021785594652\n",
      "PMC_ID:  PMC6688523\n",
      "Title:  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus\n",
      "Abstract:  Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "Has full text:  True\n",
      "\n",
      "Query:  Capabilities to discover a therapeutic (not vaccine) for the disease, and clinical effectiveness studies to discover therapeutics, to include antiviral agents.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.22823425815919252\n",
      "PMC_ID:  nan\n",
      "Title:  Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)\n",
      "Abstract:  Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.2085037850021747\n",
      "PMC_ID:  nan\n",
      "Title:  Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19\n",
      "Abstract:  In 2015, the Middle East respiratory syndrome coronavirus (MERS-CoV) reached the Republic of Korea, resulting from nosocomial transmission, and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, there are only limited therapeutic options available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including US Food and Drug Administration (FDA)-approved drugs and bioactive molecules, confirmed 221 hits by dose-response curve analysis in the primary assay, and selected 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that eight and four therapeutics act on the early- and late stages of the viral life cycle, respectively. Among the early acting drugs, three therapeutics with a TI greater than 100 were cardiotonic agents. Together, our results identify potential therapeutic options for treatment of MERS-CoV infections and could provide a basis for a wider range of coronaviruses, including the currently emerging coronavirus disease 2019 (COVID-19) outbreak.\n",
      "Has full text:  True\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.20588552541580085\n",
      "PMC_ID:  PMC2687000\n",
      "Title:  Novel Respiratory Virus Infections in Children, Brazil\n",
      "Abstract:  Recently discovered respiratory viruses were detected in 19 (9.2%) of 205 nasal swab specimens from children in Brazil with respiratory illnesses. Five each were positive for human metapneumovirus (HMPV) alone and human bocavirus (HBoV) alone, 3 for human coronaviruses (HCoV-HKU1 or -NL63) alone, and 6 for more than 1 recently discovered virus.\n",
      "Has full text:  True\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.20588552541580085\n",
      "PMC_ID:  PMC2687000\n",
      "Title:  Novel Respiratory Virus Infections in Children, Brazil\n",
      "Abstract:  Recently discovered respiratory viruses were detected in 19 (9.2%) of 205 nasal swab specimens from children in Brazil with respiratory illnesses. Five each were positive for human metapneumovirus (HMPV) alone and human bocavirus (HBoV) alone, 3 for human coronaviruses (HCoV-HKU1 or -NL63) alone, and 6 for more than 1 recently discovered virus.\n",
      "Has full text:  False\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.20232509373268714\n",
      "PMC_ID:  PMC6492651\n",
      "Title:  Advances in antivirals for noninfluenza respiratory virus infections\n",
      "Abstract:  Progress in the development of antivirals for noninfluenza respiratory viruses has been slow with the result that many unmet medical needs and few approved agents currently exist. This commentary selectively reviews examples of where specific agents have provided promising clinical benefits in selected target populations and also considers potential therapeutics for emerging threats like the SARS and Middle East respiratory syndrome coronaviruses. Recent studies have provided encouraging results in treating respiratory syncytial virus infections in lung transplant recipients, serious parainfluenza virus and adenovirus infections in immunocompromised hosts, and rhinovirus colds in outpatient asthmatics. While additional studies are needed to confirm the efficacy and safety of the specific agents tested, these observations offer the opportunity to expand therapeutic studies to other patient populations.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Alternative models to aid decision makers in determining how to prioritize and distribute scarce, newly proven therapeutics as production ramps up. This could include identifying approaches for expanding production capacity to ensure equitable and timely distribution to populations in need.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.13745443601166585\n",
      "PMC_ID:  nan\n",
      "Title:  Finding equipoise: CEPI revises its equitable access policy\n",
      "Abstract:  Launched at Davos in January 2017 with funding from sovereign investors and philanthropic institutions, the Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organisations whose mission is to stimulate, finance and co-ordinate vaccine development against diseases with epidemic potential in cases where market incentives fail. As of December 2019, CEPI has committed to investing up to $706 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (Lassa fever virus, Middle East respiratory syndrome coronavirus, Nipah virus, Chikungunya, Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X, a novel or unanticipated pathogen. As an entity largely supported by public funds, ensuring equitable access to vaccines whose development it supports in low- and middle-income countries is CEPIs primary focus. CEPI developed an initial equitable access policy shortly after its formation, with key stakeholders expressing strong views about its content and prescriptive nature. The CEPI board instructed that it be revisited after a year. This paper describes the process of revising the policy, and how key issues were resolved. CEPI will continue to take an iterative, rather than prescriptive, approach to its policyone that reflects the needs of multiple stakeholders and ensures it can meet its equitable access goals.\n",
      "Has full text:  True\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.11325687173541854\n",
      "PMC_ID:  nan\n",
      "Title:  Novel coronavirus pneumonia (COVID-19) CT distribution and sign features\n",
      "Abstract:  Objective: To investigate the imaging findings of 2019 novel coronavirus pneumonia (COVID-19). Methods: From January 20 to February 5, 2020, a total of 130 patients diagnosed with COVID-19 from seven hospitals in China were collected. The imaging data were reviewed and analyzed in detail. Results: (1) Distribution: the lesion detected in the lung unilaterally in 14 cases (10.7%) and bilaterally in 116 cases (89.3%). According to the distribution in the lobes of the lung, all cases could be classified into subpleural distribution (102 cases, 78.4%), centrilobular distribution (99 cases, 76.1%) and diffused distribution (8 cases, 6.1%). (2) Number of lesions: single lesion 9 cases (6.9%); multiple lesions 113 cases (86.9%), diffuse lesions 8 cases (6.1%). (3) Imaging density: 70 cases (53.8%) of ground-glass opacity (GGO), 60 cases (46.2%) of GGO + consolidation. (4) Accompanying signs: 100 cases (76.9%) with vascular thickening, 98 cases (75.3%) with \"pleural parallel sign\" ; \"intralobular septal thickening\" in 100 cases (76.9%); \"halo sign\" in 13 cases (10%); \"reversed-halo sign\" in 6 cases (4.6%); pleural effusion in 3 cases (2.3 %), and pneumatocele in 2 cases (1.5%); no case with pulmonary cavity. Among 35 patients that underwent follow-up CT, 21 patients (60%) improved while 14 (40%) exacerbated. Conclusions: COVID-19 imaging characteristic mainly has subpleural, centrilobular and diffused distribution. The first two distributions can overlap or progress to diffused distribution. In the later period, it was mainly manifested as organizing pneumonia and fibrosis. The most valuable characteristic is the pleural parallel sign.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.1071021411237556\n",
      "PMC_ID:  nan\n",
      "Title:  How to conduct clinical research on anesthesiology during epidemic of the novel coronavirus pneumonia: recommendations from the epidemiological perspective\n",
      "Abstract:  During the outbreak and epidemic of novel coronavirus pneumonia, anesthesiologists are not only the high-risk group of secondary infection, but also undertake tasks to initiate clinical research so that the regular pattern of disease could be summarized, which will product clinical evidences for clinical decision-making and optimization of anesthesia therapy as soon as possible. The clinical research evidences of anaesthesia are of great importance for improving the prevention and control strategy of infectious diseases and implementing relevant measures effectively. The recommendations from the epidemiological perspective are provided on how to conduct clinical research on anesthesiology during epidemic of the novel coronavirus pneumonia in the present paper: (1) The case report and case series research should be initiated promptly once the infectious cases treated in anesthesia department are diagnosed; (2) To focus on need of evidence of decision-making of diagnosis and treatment, to summarize general rules timely and to promote the rapidly production of evidence; (3) To establish a special cohort of novel coronavirus pneumonia so that more prognosis studies could be carried out; (4) To explore the risk factors which result in hospital infection among medical staffs so that hospital infection could be controlled. The purpose of this study is to provide clinicians with methodological suggestions on how to carry out high-quality clinical research in the epidemic period of infectious diseases, and to close the gap between clinical and public health.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.10188659217432072\n",
      "PMC_ID:  PMC3329003\n",
      "Title:  Nucleocapsid Protein as Early Diagnostic Marker for SARS\n",
      "Abstract:  Serum samples from 317 patients with patients with severe acute respiratory syndrome (SARS) were tested for the nucleocapsid (N) protein of SARS-associated coronavirus, with sensitivities of 94% and 78% for the first 5 days and 610 days after onset, respectively. The specificity was 99.9%. N protein can be used as an early diagnostic maker for SARS.\n",
      "Has full text:  True\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.09764859441430396\n",
      "PMC_ID:  PMC6492651\n",
      "Title:  Advances in antivirals for noninfluenza respiratory virus infections\n",
      "Abstract:  Progress in the development of antivirals for noninfluenza respiratory viruses has been slow with the result that many unmet medical needs and few approved agents currently exist. This commentary selectively reviews examples of where specific agents have provided promising clinical benefits in selected target populations and also considers potential therapeutics for emerging threats like the SARS and Middle East respiratory syndrome coronaviruses. Recent studies have provided encouraging results in treating respiratory syncytial virus infections in lung transplant recipients, serious parainfluenza virus and adenovirus infections in immunocompromised hosts, and rhinovirus colds in outpatient asthmatics. While additional studies are needed to confirm the efficacy and safety of the specific agents tested, these observations offer the opportunity to expand therapeutic studies to other patient populations.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Efforts targeted at a universal coronavirus vaccine.\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.31537106085943845\n",
      "PMC_ID:  PMC2633062\n",
      "Title:  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease\n",
      "Abstract:  An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines, such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.2873468149828937\n",
      "PMC_ID:  nan\n",
      "Title:  The SARS-CoV-2 Vaccine Pipeline: an Overview\n",
      "Abstract:  The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.28083958589222124\n",
      "PMC_ID:  PMC6356267\n",
      "Title:  Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism\n",
      "Abstract:  Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine approaches have shown efficacy in animal models and begun to enter clinical trials. In this review, we summarize the current progress towards a MERS-CoV vaccine and highlight potential roadblocks identified from previous attempts to generate coronavirus vaccines.\n",
      "Has full text:  True\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.27498999842692406\n",
      "PMC_ID:  PMC4969153\n",
      "Title:  MIDDLE EAST RESPIRATORY SYNDROME VACCINES\n",
      "Abstract:  The Middle East Respiratory Syndrome-coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No anti-viral therapies or vaccines for treatment and prophylaxis are available. Here, we discuss approaches to developing MERS vaccines, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing the human infection.\n",
      "Has full text:  nan\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.23371689110173666\n",
      "PMC_ID:  PMC6688523\n",
      "Title:  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus\n",
      "Abstract:  Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "Has full text:  True\n",
      "\n",
      "Query:  Efforts to develop animal models and standardize challenge studies\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.24387742641212973\n",
      "PMC_ID:  PMC4918159\n",
      "Title:  Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus\n",
      "Abstract:  Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.\n",
      "Has full text:  True\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.24200833333541294\n",
      "PMC_ID:  PMC4811657\n",
      "Title:  A review of genetic methods and models for analysis of coronavirus-induced severe pneumonitis\n",
      "Abstract:  Coronaviruses (CoVs) have been studied for over 60 years, but have only recently gained notoriety as deadly human pathogens with the emergence of severe respiratory syndrome CoV and Middle East respiratory syndrome virus. The rapid emergence of these viruses has demonstrated the need for good models to study severe CoV respiratory infection and pathogenesis. There are, currently, different methods and models for the study of CoV disease. The available genetic methods for the study and evaluation of CoV genetics are reviewed here. There are several animal models, both mouse and alternative animals, for the study of severe CoV respiratory disease that have been examined, each with different pros and cons relative to the actual pathogenesis of the disease in humans. A current limitation of these models is that no animal model perfectly recapitulates the disease seen in humans. Through the review and analysis of the available disease models, investigators can employ the most appropriate available model to study various aspects of CoV pathogenesis and evaluate possible antiviral treatments that may potentially be successful in future treatment and prevention of severe CoV respiratory infections.\n",
      "Has full text:  nan\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.23348064486457365\n",
      "PMC_ID:  PMC2978051\n",
      "Title:  Evaluation of Cotton Rats as a Model for Severe Acute Respiratory Syndrome\n",
      "Abstract:  Experimental studies were conducted to evaluate two species of cotton rats, Sigmodon hispidus and Sigmodon fulviventer, as a model for severe acute respiratory syndrome (SARS). Blood and turbinate wash samples, and lung tissue were collected from each animal at different time points after SARS coronavirus (CoV) infection for determining the growth curve of virus, if any, by the standard infectivity assay in Vero E6 cells. In addition, sections of the lung, liver, spleen, and kidney were taken and used for histology analysis. All animals were observed daily for signs of illness, and in some experiments, animals were weighed on the day when they were sacrificed. The results indicated that the cotton rat species, S. hispidus and S. fulviventer, were not a useful model for either SARS-CoV infection or disease. This observation was supported by the absence of any signs of illness, the failure to consistently demonstrate virus in the blood and tissues, and the absent of any notable histopathology. However, infected animals were capable of producing neuralizing antibodies against SARS-CoV, suggesting the serocon-version did occur. Further studies are warranted to consider other animal species in efforts to find better animal models for the evaluation of SARS-CoV vaccines and antiviral drugs. Key Words: Cotton ratsSARSModel animal.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.22379436371611539\n",
      "PMC_ID:  PMC4550498\n",
      "Title:  Animal models for SARS and MERS coronaviruses\n",
      "Abstract:  The emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV), two strains of animal coronaviruses that crossed the species barrier to infect and cause severe respiratory infections in humans within the last 12 years, have taught us that coronaviruses represent a global threat that does not recognize international borders. We can expect to see other novel coronaviruses emerge in the future. An ideal animal model should reflect the clinical signs, viral replication and pathology seen in humans. In this review, we present factors to consider in establishing an animal model for the study of novel coronaviruses and compare the different animal models that have been employed to study SARS-CoV and MERS-CoV.\n",
      "Has full text:  nan\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.22278120867778606\n",
      "PMC_ID:  PMC4403411\n",
      "Title:  Generation of a Transgenic Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease\n",
      "Abstract:  The emergence of Middle East respiratory syndrome-coronavirus (MERS-CoV) in the Middle East since 2012 has caused more than 900 human infections with 40% mortality to date. Animal models are needed for studying pathogenesis and for development of preventive and therapeutic agents against MERS-CoV infection. Nonhuman primates (rhesus macaques and marmosets) are expensive models of limited availability. Although a mouse lung infection model has been described using adenovirus vectors expressing human CD26/dipeptidyl peptidase 4 (DPP4), it is believed that a transgenic mouse model is needed for MERS-CoV research. We have developed this transgenic mouse model as indicated in this study. We show that transgenic mice globally expressing hCD26/DPP4 were fully permissive to MERS-CoV infection, resulting in relentless weight loss and death within days postinfection. High infectious virus titers were recovered primarily from the lungs and brains of mice at 2 and 4 days postinfection, respectively, whereas viral RNAs were also detected in the heart, spleen, and intestine, indicating a disseminating viral infection. Infected Tg(+) mice developed a progressive pneumonia, characterized by extensive inflammatory infiltration. In contrast, an inconsistent mild perivascular cuffing was the only pathological change associated with the infected brains. Moreover, infected Tg(+) mice were able to activate genes encoding for many antiviral and inflammatory mediators within the lungs and brains, coinciding with the high levels of viral replication. This new and unique transgenic mouse model will be useful for furthering knowledge of MERS pathogenesis and for the development of vaccine and treatments against MERS-CoV infection. IMPORTANCE Small and economical animal models are required for the controlled and extensive studies needed for elucidating pathogenesis and development of vaccines and antivirals against MERS. Mice are the most desirable small-animal species for this purpose because of availability and the existence of a thorough knowledge base, particularly of genetics and immunology. The standard small animals, mice, hamsters, and ferrets, all lack the functional MERS-CoV receptor and are not susceptible to infection. So, initial studies were done with nonhuman primates, expensive models of limited availability. A mouse lung infection model was described where a mouse adenovirus was used to transfect lung cells for receptor expression. Nevertheless, all generally agree that a transgenic mouse model expressing the DPP4 receptor is needed for MERS-CoV research. We have developed this transgenic mouse model as indicated in this study. This new and unique transgenic mouse model will be useful for furthering MERS research.\n",
      "Has full text:  nan\n",
      "\n",
      "Query:  Efforts to develop prophylaxis clinical studies and prioritize in healthcare workers\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#1 article\n",
      "Cosine similarity:  0.3616941910460427\n",
      "PMC_ID:  PMC3294349\n",
      "Title:  AntiSARS-CoV Immunoglobulin G in Healthcare Workers, Guangzhou, China\n",
      "Abstract:  To determine the prevalence of inapparent infection with severe acute respiratory syndrome (SARS) among healthcare workers, we performed a serosurvey to test for immunoglobulin (Ig) G antibodies to the SARS coronavirus (SARS-CoV) among 1,147 healthcare workers in 3 hospitals that admitted SARS patients in mid-May 2003. Among them were 90 healthcare workers with SARS. As a reference group, 709 healthcare workers who worked in 2 hospitals that never admitted any SARS patients were similarly tested. The seroprevalence rate was 88.9% (80/90) for healthcare workers with SARS and 1.4% (15/1,057) for healthcare workers who were apparently healthy. The seroprevalence in the reference group was 0.4% (3/709). These findings suggest that inapparent infection is uncommon. Low level of immunity among unaffected healthcare workers reinforces the need for adequate personal protection and other infection control measures in hospitals to prevent future epidemics.\n",
      "Has full text:  True\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.3175698803995879\n",
      "PMC_ID:  PMC3322937\n",
      "Title:  Lack of SARS Transmission among Healthcare Workers, United States\n",
      "Abstract:  Healthcare workers accounted for a large proportion of persons with severe acute respiratory syndrome (SARS) during the worldwide epidemic of early 2003. We conducted an investigation of healthcare workers exposed to laboratory-confirmed SARS patients in the United States to evaluate infection-control practices and possible SARS-associated coronavirus (SARS-CoV) transmission. We identified 110 healthcare workers with exposure within droplet range (i.e., 3 feet) to six SARS-CoVpositive patients. Forty-five healthcare workers had exposure without any mask use, 72 had exposure without eye protection, and 40 reported direct skin-to-skin contact. Potential droplet- and aerosol-generating procedures were infrequent: 5% of healthcare workers manipulated a patients airway, and 4% administered aerosolized medication. Despite numerous unprotected exposures, there was no serologic evidence of healthcare-related SARS-CoV transmission. Lack of transmission in the United States may be related to the relative absence of high-risk procedures or patients, factors that may place healthcare workers at higher risk for infection.\n",
      "Has full text:  True\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.2257479649798113\n",
      "PMC_ID:  PMC4806977\n",
      "Title:  Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi\n",
      "Abstract:  Middle East respiratory syndrome coronavirus (MERS-CoV) infections sharply increased in the Arabian Peninsula during spring 2014. In Abu Dhabi, United Arab Emirates, these infections occurred primarily among healthcare workers and patients. To identify and describe epidemiologic and clinical characteristics of persons with healthcare-associated infection, we reviewed laboratory-confirmed MERS-CoV cases reported to the Health Authority of Abu Dhabi during January 1, 2013May 9, 2014. Of 65 case-patients identified with MERS-CoV infection, 27 (42%) had healthcare-associated cases. Epidemiologic and genetic sequencing findings suggest that 3 healthcare clusters of MERS-CoV infection occurred, including 1 that resulted in 20 infected persons in 1 hospital. MERS-CoV in healthcare settings spread predominantly before MERS-CoV infection was diagnosed, underscoring the importance of increasing awareness and infection control measures at first points of entry to healthcare facilities.\n",
      "Has full text:  True\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.20350648760675139\n",
      "PMC_ID:  PMC3035556\n",
      "Title:  Severe Acute Respiratory Syndromeassociated Coronavirus Infection\n",
      "Abstract:  Whether severe acute respiratory syndromeassociated coronavirus (SARS-CoV) infection can be asymptomatic is unclear. We examined the seroprevalence of SARS-CoV among 674 healthcare workers from a hospital in which a SARS outbreak had occurred. A total of 353 (52%) experienced mild self-limiting illnesses, and 321 (48%) were asymptomatic throughout the course of these observations. None of these healthcare workers had antibody to SARS CoV, indicating that subclinical or mild infection attributable to SARS CoV in adults is rare.\n",
      "Has full text:  True\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.19916053981828785\n",
      "PMC_ID:  PMC5964435\n",
      "Title:  Network Analysis of MERS Coronavirus within Households, Communities, and Hospitals to Identify Most Centralized and Super-Spreading in the Arabian Peninsula, 2012 to 2016\n",
      "Abstract:  Contact history is crucial during an infectious disease outbreak and vital when seeking to understand and predict the spread of infectious diseases in human populations. The transmission connectivity networks of people infected with highly contagious Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia were assessed to identify super-spreading events among the infected patients between 2012 and 2016. Of the 1379 MERS cases recorded during the study period, 321 (23.3%) cases were linked to hospital infection, out of which 203 (14.7%) cases occurred among healthcare workers. There were 1113 isolated cases while the number of recorded contacts per MERS patient is between 1 (n=210) and 17 (n=1), with a mean of 0.27 (SD=0.76). Five super-important nodes were identified based on their high number of connected contacts worthy of prioritization (at least degree of 5). The number of secondary cases in each SSE varies (range, 517). The eigenvector centrality was significantly (p < 0.05) associated with place of exposure, with hospitals having on average significantly higher eigenvector centrality than other places of exposure. Results suggested that being a healthcare worker has a higher eigenvector centrality score on average than being nonhealthcare workers. Pathogenic droplets are easily transmitted within a confined area of hospitals; therefore, control measures should be put in place to curtail the number of hospital visitors and movements of nonessential staff within the healthcare facility with MERS cases.\n",
      "Has full text:  True\n",
      "\n",
      "Query:  Approaches to evaluate risk for enhanced disease after vaccination\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.3153351996321283\n",
      "PMC_ID:  PMC2633062\n",
      "Title:  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease\n",
      "Abstract:  An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines, such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.3009631740563308\n",
      "PMC_ID:  PMC6688523\n",
      "Title:  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus\n",
      "Abstract:  Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "Has full text:  True\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.2827046550631478\n",
      "PMC_ID:  PMC4969153\n",
      "Title:  MIDDLE EAST RESPIRATORY SYNDROME VACCINES\n",
      "Abstract:  The Middle East Respiratory Syndrome-coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No anti-viral therapies or vaccines for treatment and prophylaxis are available. Here, we discuss approaches to developing MERS vaccines, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing the human infection.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.23138397086367168\n",
      "PMC_ID:  PMC3335060\n",
      "Title:  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus\n",
      "Abstract:  BACKGROUND: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease. DESIGN: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology. RESULTS: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence. CONCLUSIONS: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.\n",
      "Has full text:  True\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#5 article\n",
      "Cosine similarity:  0.23068235287712102\n",
      "PMC_ID:  PMC6356267\n",
      "Title:  Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism\n",
      "Abstract:  Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine approaches have shown efficacy in animal models and begun to enter clinical trials. In this review, we summarize the current progress towards a MERS-CoV vaccine and highlight potential roadblocks identified from previous attempts to generate coronavirus vaccines.\n",
      "Has full text:  True\n",
      "\n",
      "Query:  Assays to evaluate vaccine immune response and process development for vaccines, alongside suitable animal models in conjunction with therapeutics\n",
      "\n",
      "#1 article\n",
      "Cosine similarity:  0.3273739521895336\n",
      "PMC_ID:  PMC2633062\n",
      "Title:  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease\n",
      "Abstract:  An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines, such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "Has full text:  nan\n",
      "\n",
      "#2 article\n",
      "Cosine similarity:  0.28793183387831633\n",
      "PMC_ID:  PMC6688523\n",
      "Title:  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus\n",
      "Abstract:  Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "Has full text:  True\n",
      "\n",
      "#3 article\n",
      "Cosine similarity:  0.27355921269246886\n",
      "PMC_ID:  PMC6355461\n",
      "Title:  Prospects for a MERS-CoV spike vaccine\n",
      "Abstract:  INTRODUCTION: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines. AREAS COVERED: In this review, we illustrate the structure and function of S protein as a vaccine target, describe available animal models for evaluating MERS vaccines, and summarize recent progress on MERS-CoV S-based vaccines, focusing on their ability to elicit antibody and/or cellular immune responses, neutralizing antibodies, and protection against MERS-CoV infection in different models. Prospects for future MERS-CoV S-based vaccines are discussed. EXPERT COMMENTARY: The majority of MERS vaccines under development are based on MERS-CoV S protein, including full-length S, S1, and receptor-binding domain (RBD). While it is essential to evaluate the safety of full-length S and S1-based MERS vaccines, further improvement of the efficacy of RBD-based vaccines using novel strategies would be necessary. Overall, this review provides informative guidance for designing and developing safe and effective MERS vaccines based on viral S protein.\n",
      "Has full text:  nan\n",
      "\n",
      "#4 article\n",
      "Cosine similarity:  0.26810479508860574\n",
      "PMC_ID:  PMC6072923\n",
      "Title:  Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models\n",
      "Abstract:  Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel betacoronavirus (MERS coronavirus, MERS-CoV). Since its first emergence in 2012, multiple transmission events of MERS-CoV (dromedary to human and human to human) have been reported, indicating that MERS-CoV has the potential to cause widespread outbreak. However, the epidemiology of MERS as well as immune responses against the virus in animal models and patients are still not well understood, hindering the vaccine and therapeutic developments. In this review, we summarize recent genetic and epidemic findings of MERS-CoV and the progress in animal model development, immune response studies in both animals and humans. At last, we discussed the breakthrough on vaccine and therapeutic development which are important against potential future MERS outbreak.\n",
      "Has full text:  nan\n",
      "\n",
      "#5 article\n",
      "Cosine similarity:  0.2601197419358763\n",
      "PMC_ID:  PMC6842459\n",
      "Title:  Evolution of infectious bronchitis virus in the field after homologous vaccination introduction\n",
      "Abstract:  Despite the fact that vaccine resistance has been typically considered a rare phenomenon, some episodes of vaccine failure have been reported with increasing frequency in intensively-raised livestock. Infectious bronchitis virus (IBV) is a widespread avian coronavirus, whose control relies mainly on extensive vaccine administration. Unfortunately, the continuous emergence of new vaccine-immunity escaping variants prompts the development of new vaccines. In the present work, a molecular epidemiology study was performed to evaluate the potential role of homologous vaccination in driving IBV evolution. This was undertaken by assessing IBV viral RNA sequences from the ORF encoding the S1 portion of viral surface glycoprotein (S) before and after the introduction of a new live vaccine on broiler farms in northern-Italy. The results of several biostatistics analyses consistently demonstrate the presence of a higher pressure in the post-vaccination period. Natural selection was detected essentially on sites located on the protein surface, within or nearby domains involved in viral attachment or related functions. This evidence strongly supports the action of vaccine-induced immunity in conditioning viral evolution, potentially leading to the emergence of new vaccine-escape variants. The great plasticity of rapidly-evolving RNA-viruses in response to human intervention, which extends beyond the poultry industry, is demonstrated, claiming further attention due to their relevance for animal and especially human health.\n",
      "Has full text:  True\n",
      "\n"
     ]
    }
   ],
   "source": [
    "nDoc = 5\n",
    "outputPath = \"../../../Downloads/2020-03-13/topArt.txt\" \n",
    "retrieveTopLiter(queries, queryDocDist, outputPath, nDoc)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We can see that most retrieved articles are highly correlated with the queries, especially for longer queries that provide a more detailed description of the information need. We also noticed that there are repeats articles in the dataset, probably due to the submission of the same article to multiple pre-print or print platforms."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Level 2: retrieve top related sentences based on cosine similarity between tf-idf vectors"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now for each retrieved article, check if a full text is available. When a full text is available, the abstracts and all paragraphs in discussion and conclusion sections (if exists) are used for sentence retrieval. When a full text is not available, only the abstract is used. All these contents are then segmented into sentences and combined for retrieving the top n related sentences for a query. The motivation behind retrieving sentences is that we are expecting the most relevant sentences may help compose a summary paragraph for each query."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [],
   "source": [
    "def findFile(name, path):\n",
    "    \"\"\"\n",
    "    Function to locate a file in a directory.\n",
    "    Input:\n",
    "        name: a string gives the name of the target file.\n",
    "        path: a string gives the directory to search the file.\n",
    "    Output:\n",
    "        return the path of the target file if the file is found. Otherwise return None.\n",
    "    \"\"\"\n",
    "    for root, dirs, files in os.walk(path):\n",
    "        if name in files:\n",
    "            return os.path.join(root, name)\n",
    "    return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieveTopSent(queries, queryDocDist, dataPath, outputPath, nDoc = 5, nSent = 10, showResults = True):\n",
    "    \"\"\"\n",
    "    Function to retrieve the top n sentences for each query based on cosine similarities between query tf-idf \n",
    "    representations and sentence tf-idf representations.\n",
    "    The retrieval is done by steps:\n",
    "        1. retrive the top nDoc literatures related to each query.\n",
    "        2. from the top nDoc literatures retrieve the top nSent sentences related to each query.\n",
    "    Input:\n",
    "        queries: a list of m strings where each string is a text normalized query.\n",
    "        queryDocDist: a m x n array that gives the pairwise cosine similarity between the m queries and n literatures.\n",
    "        dataPath: a string specifies the path to the full-text files.\n",
    "        outputPath: a string specifies the path to the output file.\n",
    "        nDoc (default 5): the number of literatures to be retrieved for each query.\n",
    "        nSent (default 10): the number of sentences to be retrieved for eacu query.\n",
    "        showResults (default True): whether show the results in the terminal.\n",
    "    \"\"\"\n",
    "    outputFile = open(outputPath, \"w\")\n",
    "    for i in range(len(queries)):\n",
    "        query = queries[i]\n",
    "        print(\"Query: \", query)\n",
    "        print(\"\")\n",
    "        outputFile.write(\"Query: \" + queries[i] + \"\\n\\n\")\n",
    "        querySents = []\n",
    "        sentPmcid = []\n",
    "        for idx in queryDocDist[i].argsort()[-nDoc:][::-1]:\n",
    "            docMeta = metaData[metaData[\"abstract\"].notnull()].iloc[idx]\n",
    "            docRepText = docMeta[\"abstract\"] # Include abstract to represent a literature\n",
    "            pmcid = docMeta[\"pmcid\"]\n",
    "            if docMeta[\"has_full_text\"] == True: # Has full text\n",
    "                sha = docMeta[\"sha\"]\n",
    "                jsonFile = findFile(sha + \".json\", dataPath) # Retrieve the full text with sha\n",
    "                if jsonFile:\n",
    "                    with open(jsonFile) as f:\n",
    "                        doc = json.load(f)\n",
    "                    for para in doc[\"body_text\"]:\n",
    "                        if para[\"section\"].lower() in [\"discussion\", \"conclusion\"]: \n",
    "                            docRepText = docRepText + \" \" + para[\"text\"] # Include paragraphs in discussion and conclusion\n",
    "            docRepSents = sent_tokenize(docRepText) # Sentence segmentation\n",
    "            querySents = querySents + docRepSents # Add sentences of this literature to all sentences related to the query\n",
    "            sentPmcid = sentPmcid + [pmcid] * len(docRepSents)\n",
    "        normQuerySents = [textNormalize(sent) for sent in querySents] # Text normalization for all sentences\n",
    "        qVectorizer = TfidfVectorizer(tokenizer = word_tokenize) # Learn a vectorizer for retrieiving sentences\n",
    "        qVectorizer.fit(normQuerySents)\n",
    "        print(\"Vocabulary size: \", len(qVectorizer.get_feature_names()))\n",
    "        print(\"\")\n",
    "        sentTermMatrix = qVectorizer.transform(normQuerySents).toarray() # Transfer sentences to sentence-term matrix\n",
    "        queryTermMatrix = qVectorizer.transform([textNormalize(query)]).toarray() # Transfer the query to query-term matrix\n",
    "        querySentDist = 1 - cdist(queryTermMatrix, sentTermMatrix, metric = 'cosine') # Compute cosine similarity\n",
    "        sentCount = 1\n",
    "        for iidx in querySentDist[0].argsort()[-nSent:][::-1]: # Show the top n related sentences\n",
    "            if np.isnan(querySentDist[0][iidx]):\n",
    "                continue\n",
    "            if showResults:\n",
    "                print(\"#\" + str(sentCount) + \" sentence\")\n",
    "                print(\"Cosine similarity: \", querySentDist[0][iidx])\n",
    "                print(\"PMC_ID: \", sentPmcid[iidx])\n",
    "                print(querySents[iidx])\n",
    "                print(\"\")\n",
    "            outputFile.write(\"#\" + str(sentCount) + \" sentence\\n\")\n",
    "            outputFile.write(\"Cosine similarity: \" + str(round(querySentDist[0][iidx], 5)) + \"\\n\")\n",
    "            outputFile.write(\"PMC_ID: \" + str(sentPmcid[iidx]) + \"\\n\")\n",
    "            outputFile.write(querySents[iidx] + \"\\n\\n\")\n",
    "            sentCount += 1\n",
    "    outputFile.close()\n",
    "    return"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query:  Effectiveness of drugs being developed and tried to treat COVID-19 patients.\n",
      "\n",
      "Vocabulary size:  257\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.5746644578519406\n",
      "PMC_ID:  nan\n",
      "How to effectively treat with existing drugs?\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.4226933344376136\n",
      "PMC_ID:  nan\n",
      "We'll soon know if covid-19 can be treated with drugs developed for HIV and Ebola, reports Alice Klein\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.3778992815065828\n",
      "PMC_ID:  nan\n",
      "What effective antiviral drugs are available?\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.2533459737563484\n",
      "PMC_ID:  nan\n",
      "How to effectively control the spread of COVID-19?\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.16419508036482944\n",
      "PMC_ID:  nan\n",
      "In the epidemic of COVID-19, front-line medical staff in emergency traumatic orthopedics is faced with great challenges in the process of diagnosing and treating patients.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.16046111540028285\n",
      "PMC_ID:  nan\n",
      "This study explains the findings from lung computed tomography images of some patients with COVID-19 treated in this medical institution and discusses the difference between COVID-19 and other lung diseases.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.14719342747782072\n",
      "PMC_ID:  nan\n",
      "COVID-19 infections were recorded in the patients and medical staff as well.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.13976335224904612\n",
      "PMC_ID:  nan\n",
      "What will eventually be the number of infected patients?\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.13379612128072593\n",
      "PMC_ID:  nan\n",
      "Results Of the 107 cases treated at the outpatient department, 3 had a definite diagnosis of COVID-19 and 3 a suspected diagnosis of COVID-19.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.10689878435001154\n",
      "PMC_ID:  nan\n",
      "Conclusions It is particularly important for medical institutions of all levels to maintain safe and effective routine services while doing well in COVID-19 prevention.\n",
      "\n",
      "Query:  Clinical and bench trials to investigate less common viral inhibitors against COVID-19 such as naproxen, clarithromycin, and minocyclinethat that may exert effects on viral replication.\n",
      "\n",
      "Vocabulary size:  354\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.32574200531893527\n",
      "PMC_ID:  PMC4178758\n",
      "Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.21787868579655356\n",
      "PMC_ID:  nan\n",
      "To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.18092482604153326\n",
      "PMC_ID:  nan\n",
      "Clinical trial for COVID-19 was first registered on January 23, 2020.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.1654600741665735\n",
      "PMC_ID:  nan\n",
      "It may be helpful to the ophthalmic clinical trial researchers and subjects during the period of novel coronavirus infection.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.1628013855376793\n",
      "PMC_ID:  nan\n",
      "Among the 125 clinical trials on treatment, 33.3% used anti-viral agents, 14.7% anti-inflammation or immunomodulators, 33.3% herbs or traditional Chinese medicine (TCM), 9.3% cell-based therapy, 2.3% antioxidation and 7.0% other approaches.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.15405296411303582\n",
      "PMC_ID:  nan\n",
      "In the last few weeks, an escalating number of clinical trials has been planned and registered with ongoing investigations taking place.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.145466669975842\n",
      "PMC_ID:  nan\n",
      "gov), there are 125 clinical trials registered by February 18, 2020, focusing on the treatment of COVID-19.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.14530636827449106\n",
      "PMC_ID:  nan\n",
      "From the Chinese Clinical Trial Registry (http://www.chictr.org.cn) and U.S. National Library of Medicine Clinical Trial Registry (https://clinicaltrials.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.14408429729859518\n",
      "PMC_ID:  nan\n",
      "In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.1369120017560591\n",
      "PMC_ID:  nan\n",
      "The N protein antibodies of SARS-CoV may cross react with COVID-19 but may not provide cross-immunity.\n",
      "\n",
      "Query:  Methods evaluating potential complication of Antibody-Dependent Enhancement (ADE) in vaccine recipients.\n",
      "\n",
      "Vocabulary size:  314\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.35032617152183976\n",
      "PMC_ID:  nan\n",
      "Antibody-dependent enhancement (ADE) of viral entry has been a major concern for epidemiology, vaccine development, and antibody-based drug therapy.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.31283323110918304\n",
      "PMC_ID:  nan\n",
      "Our study reveals a novel molecular mechanism for antibody-enhanced viral entry and can guide future vaccination and antiviral strategies.IMPORTANCE Antibody-dependent enhancement (ADE) of viral entry has been observed for many viruses.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.23085220432277587\n",
      "PMC_ID:  nan\n",
      "One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.22620873005414266\n",
      "PMC_ID:  PMC3187504\n",
      "These observations prompted us to investigate the mechanisms underlying antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.223464077693437\n",
      "PMC_ID:  nan\n",
      "We further evaluated how antibody dosages impacted viral entry into cells expressing viral receptor, Fc receptor, or both receptors.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.17654524019899387\n",
      "PMC_ID:  nan\n",
      "This study reveals complex roles of antibodies in viral entry and can guide future vaccine design and antibody-based drug therapy.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.1722475489296047\n",
      "PMC_ID:  PMC240165\n",
      "Fifty-four monoclonal antibodies (MAbs) to feline infectious peritonitis virus (FIPV) were characterized according to protein specificity, immunoglobulin subclass, virus neutralization, reactivity with different coronaviruses, and ability to induce antibody-dependent enhancement (ADE) of FIPV infection in vitro.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.17177850179351584\n",
      "PMC_ID:  PMC3187504\n",
      "We previously reported that antibody elicited by a SARS-CoV vaccine candidate based on recombinant full-length Spike-protein trimers potentiated infection of human B cell lines despite eliciting in vivo a neutralizing and protective immune response in rodents.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.1592865165186912\n",
      "PMC_ID:  PMC3187504\n",
      "Vaccination is a major strategy for containing resurgence of SARS in humans, and a number of vaccine candidates have been tested in experimental animal models.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.15765720251322768\n",
      "PMC_ID:  PMC1257724\n",
      "Antibody-dependent enhancement (ADE), a phenomenon in which viral replication is increased rather than decreased by immune sera, has been observed in vitro for a large number of viruses of public health importance, including flaviviruses, coronaviruses, and retroviruses.\n",
      "\n",
      "Query:  Exploration of use of best animal models and their predictive value for a human vaccine.\n",
      "\n",
      "Vocabulary size:  287\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.35846110621008154\n",
      "PMC_ID:  PMC3644300\n",
      "For these reasons it is imperative that animal models of disease recapitulate the human condition as closely as possible in order to provide the best predictive data with respect to the potential efficacy in humans.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.3341765870591573\n",
      "PMC_ID:  nan\n",
      "It is of great practical significance and has important implications for long-term health care to explore and analyze in the perspective of the situation of COVID-19 its philosophical values, cultural values, methodological values, social values and the national strategic value of 'healthy China'.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.3015035874341532\n",
      "PMC_ID:  PMC6688523\n",
      "In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.2594695711419345\n",
      "PMC_ID:  nan\n",
      "Here, we propose a simple econometric model that could be useful to predict the spread of COVID-2019.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.2417905053724605\n",
      "PMC_ID:  PMC2633062\n",
      "After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.19079613967784037\n",
      "PMC_ID:  nan\n",
      "Coronavirus disease 2019 (COVID-2019) has been recognized as a global threat, and several studies are being conducted using various mathematical models to predict the probable evolution of this epidemic.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.17983922608619918\n",
      "PMC_ID:  nan\n",
      "The reason lies in its multiple values.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.14352029982201953\n",
      "PMC_ID:  nan\n",
      "We performed Auto Regressive Integrated Moving Average (ARIMA) model prediction on the Johns Hopkins epidemiological data to predict the epidemiological trend of the prevalence and incidence of COVID-2019.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.1306914443870475\n",
      "PMC_ID:  PMC6688523\n",
      "As no effective treatment against MERS is currently available, therefore the best solution is to develop a functional MERS vaccine to prevent MERS-CoV infection.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.12977334331542312\n",
      "PMC_ID:  PMC3644300\n",
      "Due to this, animal models are utilized to gain insight into the pathogenesis of disease with the overall goal of identifying potential targets for intervention and evaluating specific therapeutics and vaccines.\n",
      "\n",
      "Query:  Capabilities to discover a therapeutic (not vaccine) for the disease, and clinical effectiveness studies to discover therapeutics, to include antiviral agents.\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vocabulary size:  233\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.2638823922464426\n",
      "PMC_ID:  nan\n",
      "Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.18892221691070654\n",
      "PMC_ID:  PMC6492651\n",
      "While additional studies are needed to confirm the efficacy and safety of the specific agents tested, these observations offer the opportunity to expand therapeutic studies to other patient populations.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.15654191018168073\n",
      "PMC_ID:  nan\n",
      "The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19).\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.1520366877236088\n",
      "PMC_ID:  nan\n",
      "Together, our results identify potential therapeutic options for treatment of MERS-CoV infections and could provide a basis for a wider range of coronaviruses, including the currently emerging coronavirus disease 2019 (COVID-19) outbreak.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.15015902586221053\n",
      "PMC_ID:  nan\n",
      "The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.14179659873622374\n",
      "PMC_ID:  PMC6492651\n",
      "Progress in the development of antivirals for noninfluenza respiratory viruses has been slow with the result that many unmet medical needs and few approved agents currently exist.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.13851987721391534\n",
      "PMC_ID:  nan\n",
      "Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.12806885175286353\n",
      "PMC_ID:  PMC2687000\n",
      "Recently discovered respiratory viruses were detected in 19 (9.2%) of 205 nasal swab specimens from children in Brazil with respiratory illnesses.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.12806885175286353\n",
      "PMC_ID:  PMC2687000\n",
      "Recently discovered respiratory viruses were detected in 19 (9.2%) of 205 nasal swab specimens from children in Brazil with respiratory illnesses.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.1140387594807587\n",
      "PMC_ID:  PMC6492651\n",
      "This commentary selectively reviews examples of where specific agents have provided promising clinical benefits in selected target populations and also considers potential therapeutics for emerging threats like the SARS and Middle East respiratory syndrome coronaviruses.\n",
      "\n",
      "Query:  Alternative models to aid decision makers in determining how to prioritize and distribute scarce, newly proven therapeutics as production ramps up. This could include identifying approaches for expanding production capacity to ensure equitable and timely distribution to populations in need.\n",
      "\n",
      "Vocabulary size:  310\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.2836593697763511\n",
      "PMC_ID:  nan\n",
      "According to the distribution in the lobes of the lung, all cases could be classified into subpleural distribution (102 cases, 78.4%), centrilobular distribution (99 cases, 76.1%) and diffused distribution (8 cases, 6.1%).\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.22925952770533065\n",
      "PMC_ID:  nan\n",
      "The first two distributions can overlap or progress to diffused distribution.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.20607374176735116\n",
      "PMC_ID:  PMC6492651\n",
      "While additional studies are needed to confirm the efficacy and safety of the specific agents tested, these observations offer the opportunity to expand therapeutic studies to other patient populations.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.20191986672070172\n",
      "PMC_ID:  nan\n",
      "CEPI will continue to take an iterative, rather than prescriptive, approach to its policyone that reflects the needs of multiple stakeholders and ensures it can meet its equitable access goals.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.1686796197478021\n",
      "PMC_ID:  nan\n",
      "The recommendations from the epidemiological perspective are provided on how to conduct clinical research on anesthesiology during epidemic of the novel coronavirus pneumonia in the present paper: (1) The case report and case series research should be initiated promptly once the infectious cases treated in anesthesia department are diagnosed; (2) To focus on need of evidence of decision-making of diagnosis and treatment, to summarize general rules timely and to promote the rapidly production of evidence; (3) To establish a special cohort of novel coronavirus pneumonia so that more prognosis studies could be carried out; (4) To explore the risk factors which result in hospital infection among medical staffs so that hospital infection could be controlled.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.14431781448185166\n",
      "PMC_ID:  nan\n",
      "During the outbreak and epidemic of novel coronavirus pneumonia, anesthesiologists are not only the high-risk group of secondary infection, but also undertake tasks to initiate clinical research so that the regular pattern of disease could be summarized, which will product clinical evidences for clinical decision-making and optimization of anesthesia therapy as soon as possible.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.11364616764233881\n",
      "PMC_ID:  nan\n",
      "Conclusions: COVID-19 imaging characteristic mainly has subpleural, centrilobular and diffused distribution.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.10846346471031332\n",
      "PMC_ID:  nan\n",
      "Results: (1) Distribution: the lesion detected in the lung unilaterally in 14 cases (10.7%) and bilaterally in 116 cases (89.3%).\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.10114046752834815\n",
      "PMC_ID:  PMC3329003\n",
      "N protein can be used as an early diagnostic maker for SARS.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.08916915860404229\n",
      "PMC_ID:  nan\n",
      "As an entity largely supported by public funds, ensuring equitable access to vaccines whose development it supports in low- and middle-income countries is CEPIs primary focus.\n",
      "\n",
      "Query:  Efforts targeted at a universal coronavirus vaccine.\n",
      "\n",
      "Vocabulary size:  212\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.3981386766181554\n",
      "PMC_ID:  nan\n",
      "The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.36463014378704073\n",
      "PMC_ID:  PMC6356267\n",
      "Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV) have yielded promising results.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.355462388147447\n",
      "PMC_ID:  PMC4969153\n",
      "Here, we discuss approaches to developing MERS vaccines, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.22132238049196173\n",
      "PMC_ID:  PMC2633062\n",
      "The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.19449743253553653\n",
      "PMC_ID:  PMC6356267\n",
      "In this review, we summarize the current progress towards a MERS-CoV vaccine and highlight potential roadblocks identified from previous attempts to generate coronavirus vaccines.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.1936380605007061\n",
      "PMC_ID:  PMC6688523\n",
      "In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.1550394173014794\n",
      "PMC_ID:  PMC2633062\n",
      "An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.12297989508333185\n",
      "PMC_ID:  PMC6688523\n",
      "Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.11919933317207743\n",
      "PMC_ID:  PMC2633062\n",
      "Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.11841799453440671\n",
      "PMC_ID:  PMC4969153\n",
      "The Middle East Respiratory Syndrome-coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012.\n",
      "\n",
      "Query:  Efforts to develop animal models and standardize challenge studies\n",
      "\n",
      "Vocabulary size:  285\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.3524961317532813\n",
      "PMC_ID:  PMC4918159\n",
      "Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.3411092223011234\n",
      "PMC_ID:  PMC2978051\n",
      "Further studies are warranted to consider other animal species in efforts to find better animal models for the evaluation of SARS-CoV vaccines and antiviral drugs.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.3349862450994039\n",
      "PMC_ID:  PMC4403411\n",
      "We have developed this transgenic mouse model as indicated in this study.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.3349862450994039\n",
      "PMC_ID:  PMC4403411\n",
      "We have developed this transgenic mouse model as indicated in this study.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.2845099680146932\n",
      "PMC_ID:  PMC4403411\n",
      "Animal models are needed for studying pathogenesis and for development of preventive and therapeutic agents against MERS-CoV infection.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.23044602462806862\n",
      "PMC_ID:  PMC4550498\n",
      "In this review, we present factors to consider in establishing an animal model for the study of novel coronaviruses and compare the different animal models that have been employed to study SARS-CoV and MERS-CoV.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.20841957453598725\n",
      "PMC_ID:  PMC4403411\n",
      "IMPORTANCE Small and economical animal models are required for the controlled and extensive studies needed for elucidating pathogenesis and development of vaccines and antivirals against MERS.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.20056916579524553\n",
      "PMC_ID:  PMC4403411\n",
      "The standard small animals, mice, hamsters, and ferrets, all lack the functional MERS-CoV receptor and are not susceptible to infection.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.1494335407471702\n",
      "PMC_ID:  PMC4811657\n",
      "There are several animal models, both mouse and alternative animals, for the study of severe CoV respiratory disease that have been examined, each with different pros and cons relative to the actual pathogenesis of the disease in humans.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.14391561648876183\n",
      "PMC_ID:  PMC4811657\n",
      "A current limitation of these models is that no animal model perfectly recapitulates the disease seen in humans.\n",
      "\n",
      "Query:  Efforts to develop prophylaxis clinical studies and prioritize in healthcare workers\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vocabulary size:  694\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.21577200046279787\n",
      "PMC_ID:  PMC4806977\n",
      "Supporting healthcare facilities in these efforts remains a priority.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.2115392452020094\n",
      "PMC_ID:  PMC3294349\n",
      "Some of these healthcare workers might have been misdiagnosed, as the clinical diagnosis of SARS was not specific (16) .\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.20376340279264604\n",
      "PMC_ID:  PMC3294349\n",
      "Should the disease recur there, every effort should be made to protect healthcare workers and the general public from being infected by SARS patients.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.17847189508311534\n",
      "PMC_ID:  PMC5964435\n",
      "In this study, several network centrality metrics (degree, betweenness, closeness, eigenvector, and 2-reach) were used to quantify the connectivity among MERS cases and to identify which patient requires prioritization for intervention.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.17129458704289569\n",
      "PMC_ID:  PMC3322937\n",
      "One such cluster occurred in Toronto, where illness consistent with suspected or probable SARS developed in nine healthcare workers who cared for a patient around the time of intubation, despite use of full personal protective equipment (12) .\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.16595485955832645\n",
      "PMC_ID:  PMC3294349\n",
      "This study has several limitations.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.15102260500832165\n",
      "PMC_ID:  PMC3294349\n",
      "Among them were 90 healthcare workers with SARS.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.1460905728360219\n",
      "PMC_ID:  PMC5964435\n",
      "Five super-important nodes were identified based on their high number of connected contacts worthy of prioritization (at least degree of 5).\n",
      "\n",
      "Query:  Approaches to evaluate risk for enhanced disease after vaccination\n",
      "\n",
      "Vocabulary size:  540\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.29649482339293287\n",
      "PMC_ID:  PMC3335060\n",
      "The conclusion from that experience was clear; RSV lung disease was enhanced by the prior vaccination.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.2485249283691061\n",
      "PMC_ID:  PMC3335060\n",
      "In addition to the RSV experience, concern for an inappropriate response among persons vaccinated with a SARS-CoV vaccine emanated from experiences with coronavirus infections and disease in animals that included enhanced disease among infected animals vaccinated earlier with a coronavirus vaccine [31] .\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.24177215488814785\n",
      "PMC_ID:  PMC3335060\n",
      "Feline infectious peritonitis coronavirus (FIPV) is a well-known example of antibody-mediated enhanced uptake of virus in macrophages that disseminate and increase virus quantities that lead to enhanced disease [31, 45] .\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.20198847628500305\n",
      "PMC_ID:  PMC3335060\n",
      "The emergence of the disease SARS and the rapid identification of its severity and high risk for death prompted a rapid mobilization for control at the major sites of occurrence and at the international level.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.18722078617748694\n",
      "PMC_ID:  PMC4969153\n",
      "Camel vaccination may be a novel approach to preventing the human infection.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.1780951909015911\n",
      "PMC_ID:  PMC3335060\n",
      "A summary of the SARS-CoV vaccine evaluations in animal models (including the current report) that indicated an evaluation for immunopathology after challenge is presented in Table 2 .\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.17797254808375207\n",
      "PMC_ID:  PMC3335060\n",
      "Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.17054836500740533\n",
      "PMC_ID:  PMC3335060\n",
      "For this purpose, the National Institute of Allergy and Infectious Diseases supported preparation of vaccines for evaluation for potential use in humans.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.1454807393419817\n",
      "PMC_ID:  PMC6688523\n",
      "Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.1427063188024078\n",
      "PMC_ID:  PMC4969153\n",
      "Here, we discuss approaches to developing MERS vaccines, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses.\n",
      "\n",
      "Query:  Assays to evaluate vaccine immune response and process development for vaccines, alongside suitable animal models in conjunction with therapeutics\n",
      "\n",
      "Vocabulary size:  511\n",
      "\n",
      "#1 sentence\n",
      "Cosine similarity:  0.4566062076534978\n",
      "PMC_ID:  PMC6072923\n",
      "However, the epidemiology of MERS as well as immune responses against the virus in animal models and patients are still not well understood, hindering the vaccine and therapeutic developments.\n",
      "\n",
      "#2 sentence\n",
      "Cosine similarity:  0.41706304391428684\n",
      "PMC_ID:  PMC6072923\n",
      "In this review, we summarize recent genetic and epidemic findings of MERS-CoV and the progress in animal model development, immune response studies in both animals and humans.\n",
      "\n",
      "#3 sentence\n",
      "Cosine similarity:  0.35537608095536977\n",
      "PMC_ID:  PMC6688523\n",
      "In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.\n",
      "\n",
      "#4 sentence\n",
      "Cosine similarity:  0.34046195869799223\n",
      "PMC_ID:  PMC6355461\n",
      "AREAS COVERED: In this review, we illustrate the structure and function of S protein as a vaccine target, describe available animal models for evaluating MERS vaccines, and summarize recent progress on MERS-CoV S-based vaccines, focusing on their ability to elicit antibody and/or cellular immune responses, neutralizing antibodies, and protection against MERS-CoV infection in different models.\n",
      "\n",
      "#5 sentence\n",
      "Cosine similarity:  0.3044652317214772\n",
      "PMC_ID:  PMC2633062\n",
      "After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.\n",
      "\n",
      "#6 sentence\n",
      "Cosine similarity:  0.281319686383655\n",
      "PMC_ID:  PMC6072923\n",
      "At last, we discussed the breakthrough on vaccine and therapeutic development which are important against potential future MERS outbreak.\n",
      "\n",
      "#7 sentence\n",
      "Cosine similarity:  0.24300232056062754\n",
      "PMC_ID:  PMC6842459\n",
      "IBV vaccine immunity is not sterilizing and a certain viral persistence in vaccinated animals is possible [42] .\n",
      "\n",
      "#8 sentence\n",
      "Cosine similarity:  0.20375817683418274\n",
      "PMC_ID:  PMC6842459\n",
      "Unfortunately, the continuous emergence of new vaccine-immunity escaping variants prompts the development of new vaccines.\n",
      "\n",
      "#9 sentence\n",
      "Cosine similarity:  0.17614188843659506\n",
      "PMC_ID:  PMC6688523\n",
      "In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail.\n",
      "\n",
      "#10 sentence\n",
      "Cosine similarity:  0.1718203764810582\n",
      "PMC_ID:  PMC6842459\n",
      "Since a more diversified and heterogeneous immune response spectrum has been reported to arise, the emergence of specific-immunity escaping variants could be hindered.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "nDoc = 5\n",
    "nSent = 10\n",
    "dataPath = \"../../../Downloads/2020-03-13\"\n",
    "outputPath = \"../../../Downloads/2020-03-13/topSent.txt\" \n",
    "retrieveTopSent(queries, queryDocDist, dataPath, outputPath, nDoc, nSent)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Compared to the article retrieved based on abstracts, some of the sentences retrieved here are more specifically related to the query while others only contain part of the information, which may need complement from its context."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# III. Results summary for each task"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Below we provide a mixed short-cut of selected content from articles and sentences we retrieved for the queries of each task. We have been very cautious to not overextend any conclusions or observations reported in the original articles, and only add minimal modifications to make some sentences more readable. We also provide pmcid as the reference to the article that supports each statement wherever available. The summary was written based on the articles included in the dataset, which may no longer reflect the most up-to-date research progress in this active field."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 1: What is known about transmission, incubation, and environmental stability?\n",
    "Controversy remains about whether COVID-19 has infectivity during the incubation period. A case was reported that did not show infectivity during the incubation period. Another clustering outbreak case suggested asymptomatic patients may be the key point to control the epidemic. A shorter incubation period of SARS-CoV may associate with more severe disease (PMC_ID: PMC4889459). A longer incubation period of MERS-CoV may associate with a lower risk of death (PMC_ID: PMC4766874). Longer recovery delay of MERS-CoV was seen in patients of older age, ICU admission, and abnormal radiology findings (PMC_ID: PMC6086845). Before 2012, CoV infection was found not associated with hospitalization or with increased severity of illness for children hospitalized for acute respiratory illness and/or fever (PMC_ID: PMC3288315). COVID-19 are usually mild in children while prolonged virus shedding is observed in the respiratory tract and feces at the convalescent stage. Before COVID-19, CoV generally displayed in winter seasonality between December and April, except HCoV-229E (PMC_ID: PMC2916580). Viruses other than influenza may also be important contributors to hospitalization and mortality during the peak weeks of influenza seasons, especially for the elderly (PMC_ID: PMC4281811). The role of camels in the transmission of MERS-CoV has been confirmed (PMC_ID: PMC6518552, PMC_ID: PMC6518552). Hospital-associated transmission may have a larger role than direct contact with an infected camel in the spread of MERS-CoV (PMC_ID: PMC6518552). Studies have described the ability of CoVs to survive in different environmental conditions (e.g. temperature and humidity), on different supports found in hospital settings such as aluminum, sterile sponges or latex surgical gloves or in biological fluids (PMC_ID: PMC3509683). Nasal discharge showed a higher viral positivity than feces for bovine CoV, which seemed to be associated with positive detection in the plasma (PMC_ID: PMC6068295). In an evaluation of clinical specimens from SARS patients, 34 (52%) of 66 nasopharyngeal aspirate samples from 50 patients, 5 (5%) of 94 urine samples from 94 patients, and 36 (55%) of 65 fecal samples from 65 patients tested positive for SARS CoV nucleocapsid protein (PMC_ID: PMC446266). Pathogenic CoV-229E remained infectious in a human lung cell culture model following at least 5days of persistence on a range of common nonbiocidal surface materials, including polytetrafluoroethylene (Teflon; PTFE), polyvinyl chloride (PVC), ceramic tiles, glass, silicone rubber, and stainless steel (PMC_ID: PMC4659470). CoV-229E was rapidly inactivated on a range of copper alloys (within a few minutes for simulated fingertip contamination) and Cu/Zn brasses were very effective at lower copper concentration. Exposure to copper destroyed the viral genomes and irreversibly affected virus morphology, including disintegration of envelope and dispersal of surface spikes (PMC_ID: PMC4659470). Most viruses from the respiratory tract, including SARS, can persist on surfaces for a few days (PMC_ID: PMC1564025). The analysis of 22 studies reveals that human coronaviruses such as SARS-CoV, MERS-CoV or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 6271% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute. Alpacas may be suitable models for infection and shedding dynamics of MERS-CoV (PMC_ID: PMC4880109). Rhesus macaque and common marmoset have been established as animal models for MERS-CoV (PMC_ID: PMC4140844). A current limitation of animal models for CoV is that no animal model perfectly recapitulates the disease seen in humans (PMC_ID: PMC4811657). No evidence was found of changes in the evolutionary rate of MERS-CoV and no reason to suspect adaptive changes in viral proteins (PMC_ID: PMC4734539). Many, if not all, viruses, including CoV, suppress innate immune responses to gain a window of opportunity for efficient virus replication and setting-up of the infection (PMC_ID: PMC6959104). Potential targets have been identified for immune responses to COVID-19 and provide essential information for understanding human immune responses to this virus and evaluation of diagnostic and vaccine candidates. For SARS-CoV, the humoral immune response was enhanced most effectively through the use of inactivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but not the CD8 response (PMC_ID: PMC1280202). MERS-CoV and SARS-CoV have evolved diverse strategies to evade and block host immune responses, facilitating infection and transmission (PMC_ID: PMC4821769).  Full precautions should be applied and carefully followed to prevent the transmission of MERS-CoV, especially among health care workers (PMC_ID: PMC6695009). For SARS-CoV, a study reported that there was no evidence of transmission of infection before symptom onset (PMC_ID: PMC2870589). The patients treated in the burn and wound care ward are susceptible to viral infection because of disease, age and other factors, so it is very important to manage the burn and wound care ward during the prevention and control of CoV epidemic. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. Contaminated surfaces may play a major role in transmission of SARS-CoV in the hospital and the community (PMC_ID: PMC3265313). The better stability of SARS-CoV at low temperature and low humidity environment may facilitate its transmission in community in subtropical area (such as Hong Kong) during the spring and in air-conditioned environments (PMC_ID: PMC3265313). In countries such as Singapore and Hong Kong where there is an intensive use of air-conditioning, transmission of SARS-CoV largely occurred in well-air-conditioned environments such as hospitals or hotels (PMC_ID: PMC3265313)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 2: What do we know about COVID-19 risk factors?\n",
    "Evidence of an impact of legislative bans on smoking prevalence and tobacco consumption is inconsistent, with some studies not detecting additional longterm change in existing trends in smoking prevalence or impact on respiratory and perinatal health outcomes (PMC_ID: PMC6486282). Coronavirus infection should be considered in differential diagnosis of respiratory tract illness in adults including those that require hospitalization, have a history of smoking and have pulmonary comorbidities (PMC_ID: PMC5631947). Pulmonary function testing procedures have been associated with an increasing risk of COVID-19 transmission among patients/subjects and medical staffs. It is strongly recommended to suspend the pulmonary function test for the confirmed or suspected cases of COVID-19 during the contagious stage, and to postpone the test for other patients if it is not imperative. H1N1 patients coinfected with rhinovirus had less severe disease while non-rhinovirus co-infections were associated with substantially higher severity without changes in influenza viral titer (PMC_ID: PMC3153592). There was a significant decrease in the duration of influenza A viral shedding in co-infections (of any respiratory viruses) compared to single infections (PMC_ID: PMC6625191). Respiratory viruses rarely reach their epidemic peak concurrently and there appears to be a negative association between infection with one respiratory virus and co-infection with another (PMC_ID: PMC6625191). Co-detections of specific clusters of viruses were observed in 9% of acute respiratory illness cases particularly in children, were less frequent in households without children, and were less symptomatic (e.g., lower fever) than single infections (PMC_ID: PMC4344779). Most frequently co-detected viruses were coronavirus, respiratory syncytial virus, and influenza A virus (PMC_ID: PMC4344779). Co-infection was less likely with increasing age, which may be a consequence of pre-existing immunity or decreased viral shedding with increasing age (PMC_ID: PMC6625191). Infection by rhinovirus may result in temporary immunity of the host to infection by other respiratory viruses due to the production of cytokines, thus resulting in a negative association between rhinovirus infection and co-infection with another virus (PMC_ID: PMC6625191). So far, no maternal deaths have been reported for women with COVID-19. There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy. There is no evidence suggesting transplacental transmission based on very limited data, as the analysis of amniotic fluid, cord blood, neonatal throat swab, and breast milk samples available from six of the nine patients were found to be negative for COVID-19. Whether virus shedding occurs vaginally is also not known. In general, the clinical characteristics of the pregnant women with COVID-19 pneumonia were similar to those of non-pregnant adult patients who developed COVID-19 pneumonia. Another study reported that the impact of COVID-19 infection on pregnant women appears to be less severe. Both SARS coronavirus and H7N9 viruses presented a global epidemic threat, but the social and economic impacts of H7N9 were not as serious as in the case of SARS because the response to H7N9 was more effective (PMC_ID: PMC6046118). A mathematical model for MERS-CoV transmission dynamics has been used to estimate the transmission rates in two periods due to the implementation of intensive interventions (PMC_ID: PMC4776270). The serial interval of COVID-19 is close to or shorter than its median incubation period. This suggests that a substantial proportion of secondary transmission may occur prior to illness onset. The COVID-19 serial interval is also shorter than the serial interval of severe acute respiratory syndrome (SARS), indicating that calculations made using the SARS serial interval may introduce bias. Among patients infected with a respiratory virus, risk of hospitalization was higher among underweight adult patients, and obese patients had a longer mean length of stay once hospitalized (PMC_ID: PMC6809817). Underweight children were not at increased risk of hospitalization (PMC_ID: PMC6809817). For MERS-CoV, increased age and underlying comorbidity were risk factors for both death and severe disease, while cases arising in Saudi Arabia were more likely to be severe (PMC_ID: PMC5023790). There is no significant association between alleles or genotypes of the MASP2 tagSNP and susceptibility to SARS-CoV in both Beijing and Guangzhou populations (PMC_ID: PMC2683852). MASP2 polymorphisms is not directly related to SARS-CoV susceptibility in northern and southern Chinese (PMC_ID: PMC2683852). Strong infection control and response measures were effective in controlling the outbreak of MERS-CoV in the Republic of Korea (PMC_ID: PMC4957609). Two of the most effective policy procedures to prevent infections of SARS-CoV would be to apply stringent precautionary measures and to impose quicker and more effective quarantine of the exposed populace (PMC_ID: PMC1732706)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 3: What do we know about virus genetics, origin, and evolution?\n",
    "A web-based tool (SummaryGenome Detective) was developed to allow tracking of new viral mutations as the outbreak expands globally, which may help to accelerate the development of novel diagnostics, drugs and vaccines to stop the COVID-19 disease. A web-based portal (WashU Virus Genome Browser) was developed for viewing virus genomic data, which is home to 16 complete 2019-nCoV genome sequences, together with hundreds of related viral sequences including SARS-CoV, MERS-CoV, and Ebola virus. Genetic and epidemiological evidence indicate camels serve as a reservoir for MERS virus (PMC_ID: PMC4720378). The emergence of MERS-CoV was believed to be of zoonotic origin from bats with dromedary camels as intermediate hosts. There is a likelihood of other domestic livestock serving as intermediate hosts for this virus (PMC_ID: PMC6473935). RNA-RNA recombination may play a significant role in natural evolution and neuropathogenesis of coronaviruses (PMC_ID: PMC253235). It is unclear whether higher virus load causally leads to severe outcomes of MERS-CoV (PMC_ID: PMC4622256). Wildlife trade can facilitate zoonotic disease transmission and represents a threat to human health and economies in Asia, highlighted by the 2003 SARS coronavirus outbreak, where a Chinese wildlife market facilitated pathogen transmission (PMC_ID: PMC4805265). Highly pathogenic viruses elicit expression of many of the same key genes as lower pathogenic viruses but to a higher degree. This increased degree of expression may result in the uncontrolled co-localization of inflammatory cell types and lead to irreversible host damage (PMC_ID: PMC3297540). In addition to SARS, the highly pathogenic avian influenza virus (AIV), H5N1, and the lower pathogenicity H9N2 AIV have expanded their host ranges to infect human beings and other mammalian species as well as birds (PMC_ID: PMC2865088). Viruses that originate in bats may be the most notorious emerging zoonoses that spill over from wildlife into domestic animals and humans (PMC_ID: PMC4262174). Transmission of viruses from bats to humans requires a hierarchy of enabling conditions that connect the distribution of reservoir hosts, viral infection within these hosts, and exposure and susceptibility of recipient hosts (PMC_ID: PMC4262174). The advancements in metagenomic techniques have allowed the identification of SARS-like coronaviruses (SL-CoVs) sequences that share high homology to the human SARS-CoV epidemic strains from wildlife bats, presenting concrete evidence that bats are the origin and natural reservoir of SARS-CoV (PMC_ID: PMC5287300). Demographic factors, such as race, smoking status, and socioeconomic status, may confer an increased risk of susceptibility to viruses including CoV (PMC_ID: PMC2593164)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 4: What do we know about vaccines and therapeutics?\n",
    "Drugs developed for HIV and Ebola are being tested for treating COVID-19. In the epidemic of COVID-19, front-line medical staff in emergency traumatic orthopedics is faced with great challenges in the process of diagnosing and treating patients. Lung computed tomography images are being used for supporting the diagnosis of COVID-19. It is considered particularly important for medical institutions of all levels to maintain safe and effective routine services while doing well in COVID-19 prevention. Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease (PMC_ID: PMC4178758). To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China for COVID-19. From the Chinese Clinical Trial Registry (http://www.chictr.org.cn) and U.S. National Library of Medicine Clinical Trial Registry (https://clinicaltrials. gov), there are 125 clinical trials registered by February 18, 2020, focusing on the treatment of COVID-19. There is an upward trend on the number of registered clinical trials (Figure 1). Among the 125 clinical trials on treatment, 33.3% used anti-viral agents, 14.7% anti-inflammation or immunomodulators, 33.3% herbs or traditional Chinese medicine (TCM), 9.3% cell-based therapy, 2.3% antioxidation and 7.0% other approaches. Studies suggest that the human receptor for COVID-19 may be angiotensin-converting enzyme 2 (ACE2) receptor similar to that of SARS-CoV. The nucleocapsid (N) protein of COVID-19 has nearly 90% amino acid sequence identity with SARS-CoV. The N protein antibodies of SARS-CoV may cross react with COVID-19 but may not provide cross-immunity. Antibody-dependent enhancement (ADE) of viral entry has been a major concern for epidemiology, vaccine development, and antibody-based drug therapy. The discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world may due to the antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses. Antibody-dependent enhancement (ADE), a phenomenon in which viral replication is increased rather than decreased by immune sera, has been observed in vitro for a large number of viruses of public health importance, including flaviviruses, coronaviruses, and retroviruses (PMC_ID: PMC1257724). Vaccination is a major strategy for containing resurgence of SARS in humans, and a number of vaccine candidates have been tested in experimental animal models (PMC_ID: PMC3187504). In general, the potential vaccine candidates for MERS-CoV can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine (PMC_ID: PMC6688523). Animal models are utilized to gain insight into the pathogenesis of disease with the overall goal of identifying potential targets for intervention and evaluating specific therapeutics and vaccines (PMC_ID: PMC3644300). MERS-CoV has been used to screen FDA-approved drugs identify potential therapeutic options for treatment of MERS-CoV infections and provide a basis for potential therapeutic options for COVID-19. COVID-19 imaging characteristic mainly has subpleural, centrilobular and diffused distribution. N protein can be used as an early diagnostic maker for SARS (PMC_ID: PMC3329003). Several types of vaccines have been developed for SARS-CoV including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics (PMC_ID: PMC2633062). Transgenic mouse model has been developed for MERS-CoV (PMC_ID: PMC4403411). The standard small animals, mice, hamsters, and ferrets, all lack the functional MERS-CoV receptor and are not susceptible to infection (PMC_ID: PMC4403411). Camel vaccination for MERS-CoV may be a novel approach to preventing the human infection (PMC_ID: PMC4969153). For SARS-CoV, evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease (PMC_ID: PMC3335060). The majority of MERS vaccines under development are based on MERS-CoV S protein, including full-length S, S1, and receptor-binding domain (RBD). (PMC_ID: PMC6355461)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 5: What has been published about medical care?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 6: What do we know about non-pharmaceutical interventions?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 7: Sample task with sample submission"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 8: What do we know about diagnostics and surveillance?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 9: What has been published about ethical and social science considerations?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Task 10: What has been published about information sharing and inter-sectoral collaboration?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
